

10010929 1221001S

FORM PTO-1390  
(REV. 9-2001)

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

**TRANSMITTAL LETTER TO THE UNITED STATES  
DESIGNATED/ELECTED OFFICE (DO/EO/US)  
CONCERNING A FILING UNDER 35 U.S.C. 371**

ATTORNEY'S DOCUMENT

S-31005A

U.S. APPLICATION NO. (If known, see 37 CFR 1.5)

**10/018929**

INTERNATIONAL APPLICATION NO.  
PCT/EP00/05761

INTERNATIONAL FILING DATE  
June 21, 2000

PRIORITY DATE CLAIMED  
June 23, 1999

**TITLE OF INVENTION**

Gene Involved in Epigenetic Gene Silencing

**APPLICANT(S) FOR DO/EO/US**

Yoshiki Habu et al.

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. ☒ This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
2. ☐ This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
3. ☒ This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (21) indicated below.
4. ☐ The US has been elected by the expiration of 19 months from the priority date (Article 31).
5. ☒ A copy of the International Application as filed (35 U.S.C. 371(c)(2))
  - a. ☒ is attached hereto (required only if not communicated by the International Bureau).
  - b. ☐ has been communicated by the International Bureau.
  - c. ☐ is not required, as the application was filed in the United States Receiving Office (RO/US).
6. ☐ An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)).
  - a. ☐ is attached hereto.
  - b. ☐ has been previously submitted under 35 U.S.C. 154(d)(4).
7. ☒ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))
  - a. ☒ are attached hereto (required only if not communicated by the International Bureau).
  - b. ☐ have been communicated by the International Bureau.
  - c. ☐ have not been made; however, the time limit for making such amendments has NOT expired.
  - d. ☐ have not been made and will not be made.
8. ☐ An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371 (c)(3)).
9. ☒ An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).
10. ☐ An English language translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).

**Items 11 to 20 below concern document(s) or information included:**

11. ☐ An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
12. ☒ An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
13. ☒ A **FIRST** preliminary amendment.
14. ☐ A **SECOND** or **SUBSEQUENT** preliminary amendment.
15. ☐ A substitute specification.
16. ☐ A change of power of attorney and/or address letter.
17. ☒ A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 35 U.S.C. 1.821 - 1.825.
18. ☐ A second copy of the published international application under 35 U.S.C. 154(d)(4).
19. ☐ A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4).
20. ☒ Other items or information: Certified Copy of Priority Document GB 9914623.5

21. ☒ The following fees are submitted:**BASIC NATIONAL FEE (37 CFR 1.492 (a) (1) - (5)):**Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO. .... **\$1040.00**International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO ..... **\$890.00**International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO ..... **\$740.00**International preliminary examination fee (37 CFR 1.482) paid to USPTO but all claims did not satisfy provisions of PCT Article 33(1)-(4) ..... **\$710.00**International preliminary examination fee (37 CFR 1.482) paid to USPTO and all claims satisfied provisions of PCT Article 33(1)-(4) ..... **\$100.00****ENTER APPROPRIATE BASIC FEE AMOUNT =****CALCULATIONS PTO USE ONLY**

\$ 890.00

Surcharge of **\$130.00** for furnishing the oath or declaration later than ☐ 20 ☐ 30 months from the earliest claimed priority date (37 CFR 1.492(e)).

\$

CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE	
Total claims	16 - 20 =		x <b>\$18.00</b>	\$
Independent claims	2 - 3 =		x <b>\$84.00</b>	\$
MULTIPLE DEPENDENT CLAIM(S) (if applicable)			+ <b>\$280.00</b>	\$

\$

**TOTAL OF ABOVE CALCULATIONS =**

\$

☐ Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above are reduced by 1/2.

\$

**SUBTOTAL =**

\$

Processing fee of **\$130.00** for furnishing the English translation later than ☐ 20 ☐ 30 months from the earliest claimed priority date (37 CFR 1.492(f)).

\$

**TOTAL NATIONAL FEE =**

\$

Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). **\$40.00** per property +

\$40.00

**TOTAL FEES ENCLOSED =**

\$ 930.00

Amount to be refunded:

\$

charged:

\$

- a. ☐ A check in the amount of \$ \_\_\_\_\_ to cover the above fees is enclosed.
- b. ☐ Please charge my Deposit Account No. \_\_\_\_\_ in the amount of \$ \_\_\_\_\_ to cover the above fees. A duplicate copy of this sheet is enclosed.
- c. ☒ The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 50-1744. A duplicate copy of this sheet is enclosed.
- d. ☒ Fees are to be charged to a credit card. **WARNING:** Information on this form may become public. **Credit card information should not be included on this form.** Provide credit card information and authorization on PTO-2038.

**NOTE:** Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137 (a) or (b)) must be filed and granted to restore the application to pending status.SEND ALL CORRESPONDENCE TO:  
Customer Number 22847

SIGNATURE

Marcia Morton

NAME

46,942

REGISTRATION NUMBER

10018929 122101

531 Rec'd PC

21 DEC 2001

**FILING BY "EXPRESS MAIL" UNDER 37 § C.F.R. 1.10**

I hereby certify that the following correspondence is being deposited with the United States Postal Service as "Express Mail Post Office to Addressee" in an envelope addressed to: BOX PCT, U.S. Patent and Trademark Office, P.O. Box 2327, Arlington VA, 22202 under Express Mail Label No. ET327548859US on December 21, 2001.

- 1) Transmittal Letter to the United States Designated/Elected Office (DO/EO/US) Concerning a Filing Under 35 U.S.C. 371 (FORM PTO-1390)
- 2) Copy of International Application As Filed
- 3) Amendment to the Claims of the International Application under PCT Article 19
- 4) Certified Copy of Priority Document GB 9914623.5
- 5) Recordation Form Cover Sheet
- 6) Assignment (2 sheets total)
- 7) Declaration and Power of Attorney for United States Application (2 total)
- 8) First Preliminary Amendment
- 9) A Computer-Readable Form and Paper Copy of the Sequence Listing and Statement of Verification
- 10) Credit Card Payment Form

Melissa Hardy  
Name

Melissa Hardy  
Signature

10018929 JP2101  
10/010/27  
531 Rec'd PCT/F 21 DEC 2001

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re application of:

Habu *et al.*

Serial Number: TBA

Filed: December 21, 2001

For: Gene Involved in Epigenetic Gene  
Silencing

Art Unit: TBA

Examiner: TBA

Atty Docket: S-31005A

**PRELIMINARY AMENDMENT**

BOX PCT  
U.S. Patent and Trademark Office  
P.O. Box 2327  
Arlington, VA 2202

Sir:

Applicants respectfully request that the above-captioned application be amended as follows  
in advance of prosecution:

**IN THE SPECIFICATION:**

At page 1, after the title, please insert:

This application is a § 371 of International Application No. PCT /EP00/05761, filed  
June 21, 2000.

**IN THE CLAIMS**

Please amend claim 8 as follows:

8. (Amended) The protein encoded by the open reading frame of claim 1.

Please add the following new claims:

11. (New) The protein encoded by the open reading frame of claim 2.

12. (New) The protein encoded by the open reading frame of claim 3.

13. (New) The protein encoded by the open reading frame of claim 4.
14. (New) The protein encoded by the open reading frame of claim 5.
15. (New) The protein encoded by the open reading frame of claim 6.
16. (New) The protein encoded by the open reading frame of claim 7.

### REMARKS


The claims have been amended to eliminate multiple dependency and to ensure that they are in compliance with the rules of U.S. practice. No new matter has been added by these amendments.

If in the opinion of the Examiner, a telephone conference would expedite the prosecution of the subject application, the Examiner is invited to call the undersigned attorney.

The Commissioner has been authorized to charge the fees associated with the filing of the application which this amendment accompanies and associated papers to Applicant's credit card. If there are any additional fees required, authorization is hereby provided to charge such fees to Applicant's Deposit Account No. 50-1744 (in the name of Syngenta Biotechnology, Inc.).

Respectfully submitted,

Syngenta Biotechnology, Inc.  
Patent Department  
P.O. Box 12257  
Research Triangle Park, NC 27709-2257  
(919) 541-8566  
December 21, 2001

  
\_\_\_\_\_  
Marcia R. Morton  
Attorney for Applicants  
Reg. No. 46,942

**Version With Markings To Show Changes Made**

The claims have been amended as follows:

8. (Amended) The protein encoded by the open reading frame of claim 1 [any one of claims 1 to 7].
- 11. (New) The protein encoded by the open reading frame of claim 2.
12. (New) The protein encoded by the open reading frame of claim 3.
13. (New) The protein encoded by the open reading frame of claim 4.
14. (New) The protein encoded by the open reading frame of claim 5.
15. (New) The protein encoded by the open reading frame of claim 6.
16. (New) The protein encoded by the open reading frame of claim 7.

10018929.122101

10/018929

S-31005A

21 DEC 2001

531 Rec'd PC

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

ART UNIT: TBA

Habu *et al.*

EXAMINER: TBA

SERIAL NO: TBA

FILED: Even Date Herewith

FOR: Gene Involved in Epigenetic Gene Silencing

BOX PCT  
U.S. Patent and Trademark Office  
P.O. Box 2327  
Arlington, VA 22202


**SUBMISSION OF SEQUENCE LISTING  
INCLUDING STATEMENT OF VERIFICATION**

Sir:

Applicant hereby provides a Computer Readable Form of the Sequence Listing as well as the Paper Copy thereof. The undersigned states that the Paper Copy and the Computer Readable Form, submitted in accordance with 37 CFR §1.821(c) and (e), respectively, are the same.

Respectfully submitted,

Syngenta Biotechnology, Inc.  
Patent Department  
P.O. Box 12257  
Research Triangle Park, NC 27709-2257

  
Marcia R. Morton  
Attorney for Applicants  
Reg. No. 46,942  
(919) 541-8566

Date: December 21, 2001

10/018929

- 1 -

531 Rec'd PCT

21 DEC 2001

## SEQUENCE LISTING

<110> Novartis AG  
Novartis Research Foundation

<120> Gene involved in epigenetic gene silencing

<130> S-31005A

<140>  
<141>

<150> GB 9914623.5  
<151> 1999-06-23

<160> 33

<170> PatentIn Ver. 2.1

<210> 1  
<211> 10329  
<212> DNA  
<213> Arabidopsis thaliana

<220>  
<221> intron  
<222> (1009) .. (1295)

<220>  
<221> intron  
<222> (2551) .. (2673)

<220>  
<221> intron  
<222> (2753) .. (2867)

<220>  
<221> intron  
<222> (3114) .. (3506)

<220>  
<221> intron  
<222> (3681) .. (3973)

<220>  
<221> intron  
<222> (4896) .. (4975)

<220>  
<221> intron  
<222> (5218) .. (5777)

<220>  
<221> intron



- 2 -

&lt;222&gt; (5883) .. (6082)

&lt;220&gt;

&lt;221&gt; intron

&lt;222&gt; (7481) .. (7615)

&lt;220&gt;

&lt;221&gt; intron

&lt;222&gt; (7772) .. (7914)

&lt;220&gt;

&lt;221&gt; intron

&lt;222&gt; (8071) .. (8153)

&lt;220&gt;

&lt;221&gt; intron

&lt;222&gt; (8319) .. (8451)

&lt;220&gt;

&lt;221&gt; intron

&lt;222&gt; (8630) .. (8718)

&lt;220&gt;

&lt;221&gt; intron

&lt;222&gt; (8919) .. (9000)

&lt;220&gt;

&lt;221&gt; intron

&lt;222&gt; (9212) .. (9284)

&lt;400&gt; 1

```

aatatttaag tttggtttat attcttttcta gtaatctttg aaatattgta agagataatg 60
cttctaataa ataacattgg atttattgga attaatgtat tgaaaaaact atgcaaatac 120
tacagtgtat tttggaacga ccaaaatgat atatgtaaac tttcgttcta gtctttctaca 180
tagtgttaata ggatagcgga caaggttgat cgactctaaa cattatgggt acgtaattcc 240
gcagtgggta cagtctactg tcgaggccaa actggtaatt aaacgtttga agtttagaga 300
aatattttga tgatgagtac cacaatcaaa gatgataggt gttaatcact gtaaaaatgt 360
tgattgaata ctacgaatgc agaacatata catattttta atctctttgg aatttttggt 420
tttgttttta tcatttttga atacacgaag agctcagtta tatttcatat tgtatatgaa 480
tttgttctat ttaatcttca attctagcaa cataacttta tgctaattcg tttcatattt 540
tagtatagta taaaaattac aaatttcaaa acaaaactata agtaatatac taacatagtc 600
gggtgaacat ttcggttaatt tcacataaca tatgttaatt acatatgtac actatttttg 660
aagtatttta taacttaaaa tatataaatt taaatctaag aaatcacaag catgagtttt 720
tccttccggt aatcgtaaaa tcaaaaatcg ctgcgtcgag aaacgccggt gctagaagag 780
gaaagtaccg tacataatcc tgcaaccca attctcgtct tcttcaaact cagttttccg 840
aaaccccaaa caccgcgagg attgcatggc ctgaagaacc acttaatcga gaattgtgct 900
ggaattctca aattttccct cgcgtttttc tttcacactc tcggaatcgg aaatttccac 960
caagctccgt caagcgatag attctgacaa ttacacactt tcgcgcaggt atgcttccct 1020
ccctgtttta gggtgggtgtt aatctatcgg tgaatcgaag gttttgggcc tcgggctttg 1080
cgttttaggt ttttcagaga atcttatcta cttggggatg gatcttaggc gtttgtaga 1140
tgtaactcat tagttttgca tataggaatt ttgatttgaa agtttaggtcg ccggatttgt 1200
agacattttg tttgatggtc ttcttcggtg ctcacattct ttgtttttaa gtgcttgatt 1260
tggttgctaa ggtcctttcc gttgcgtgct ctcagtgaat atgaagaaag atgaaaagat 1320
tggtttgacg gggagaacca tttacaccag atccctagca gcttcaattc ctgcctcagt 1380
tgaacaagaa acccctgggt tgaggaggtc aagccggggg acaccatcta cgaaggtaat 1440

```

- 3 -

aactccagct	tctgctacta	gaaagtcaga	gagactggct	ccctcacctg	cttcagtttc	1500
aaaaaagtc	ggtggaatcg	tcaagaattc	cacaccaagt	tctttgcgaa	ggtccaatag	1560
ggggaagact	gaagtatcct	tgcagagttc	caaaggatca	gataattcta	tcaggaaagg	1620
agatacttca	ccggatattg	agcagagaaa	ggatagtgtt	gaagagtcga	cagataagat	1680
caagcctata	atgtcagccc	gaagttacag	ggcattgttt	agagggaagc	tcaaggaatc	1740
tgaggcatta	gttgatgctt	ccccaaatga	agaggaacta	gtagtgtgtg	gttgttctcg	1800
ccgcatacct	gcaggcaatg	atgatgttca	aggtaaaaca	gattgtccac	cacctgcaga	1860
tgcaggatca	aaaaggtcgc	cagttgacga	aactagtttg	gacaagggca	ctgattttcc	1920
tttgaaatca	gttacggaga	ccgagaagat	agtgtttgat	gcacccccca	tagttgaaac	1980
tggggatgac	agtgttatag	gttcaccatc	tgagaattta	gagacacaaa	agcttcaaga	2040
tggtaaagaca	gattgtttcac	cacttgcaaa	tgcagaatcg	aaaacgctgc	cagttgggtga	2100
aactagttta	gaaaaagaat	atccacaaaa	gtttcaagat	gataacacag	attgtctacc	2160
acctgcaaat	gcagaatcaa	aaaggctgcc	agttggcgaa	actagtttag	aaaaggacac	2220
tgatttttct	ttgaaatcaa	ctacggagac	tggaaagatg	gttctttatg	catcccccat	2280
agttgaaact	agggatgaca	gcgttatatg	ttcaccatct	acaaatttag	aaacccaaaa	2340
gcttctgtgc	agtaaaactg	gcttagaaac	cgacatagtt	ttgcctttga	aaagaaaaag	2400
agacactgca	gaaattgagc	tggatgcatg	tgctacagtt	gcaaattggag	atgatcacgt	2460
tatgagttct	gatgggggtca	ttccatctcc	atctgggtgc	aaaaatgata	atcgacctga	2520
aatgtgcaac	acgtgtaaaa	aacggcaaaa	gtaagagttt	ttttagtgtt	gtctgtctat	2580
tgaaacgac	tgccaatggt	gaatgttggg	cagatgggtt	tgattcttag	gatatatggt	2640
ctgtattgtg	atgagttggt	caaaattttg	aaggggtcaac	ggtgattgtc	aaaataggag	2700
tgtttgctcc	tgcattgtcc	agccagttga	agaatctgat	aacgtgacac	aggttgggtt	2760
ctaattactt	tcggagaccc	gttaatcagt	ggactcttaa	atagttagat	actagattta	2820
cttatctttt	tacttgtaat	ctgcaattct	attttgcatt	tgattaggat	atgaaagaaa	2880
ctggaccagt	tacgagcaga	gaatatgagg	agaacgggca	aatacaacat	ggtaaatcaa	2940
gtgatcccaa	attctattct	tcggtgtacc	cagagtattg	ggttcctgtg	cagctatcag	3000
atgtacagct	ggagcaatac	tgtcagactc	tcttctccaa	atccttatct	ctttcttcac	3060
tttcgaagat	tgatcttgga	gctctagaag	aaactctcaa	ttctgtaaga	aaagtaagtt	3120
acttgatttt	aaaaacactt	attcttcaat	gcacttgtga	gttaagtacc	cagttattac	3180
tgggtgataag	ataaagaaag	caatagaaaa	attgataagg	tgttcaccgc	attgcagcca	3240
aaaaaacaat	tgtgtgttcc	atgctttcaa	gaggttgtca	catagggtgt	atgcctttct	3300
gtttgatgct	tggtagagca	aagggtttgg	gtctatttgt	tttatgcttt	tttgaaacac	3360
atagaacctg	gcaaaactga	cagtttttgg	gttgcttaga	tatacgacta	ttgtcgggtca	3420
gcacacattt	ttctcaaggc	ctctttctgc	atgttaatgt	gtgaatatat	taaaatcttc	3480
tttatgtggt	tgcaacttgt	tgacagacct	gtgaccatcc	atacgttatg	gatgcatctt	3540
tgaacaactt	gctcaccaag	aatctggagt	tgcatgaaat	cctggatgta	gaaattaaag	3600
cgagcgggaa	acttcacctc	cttgataaaa	tgcttactca	tataaaaaag	aatggtttta	3660
aagcagttgt	cttctaccag	gtgcattttc	tattacttgc	gaatgtgaat	agctctatgt	3720
ttgtcatgaa	tacgtcaact	tgtgcattct	caatatatgt	gcattttctt	tttgacaatg	3780
gaattctgtc	ttgtattgaa	atttgagtgg	gatgaaagta	tgctttttat	cgtgcaatta	3840
tgaagtgtaa	gttagccttc	agcagtcagc	tagcattatg	agatatgctg	aactaaaatg	3900
tttcttttct	cttcttttct	tttcggtata	tgctcctcat	gtatgtttga	attacagttt	3960
ttattttcag	caggcaacac	aaaccctga	agggcttctg	cttggttaata	ttctcgaaga	4020
ttttgtgggt	caaagatttg	gtccaaaatc	ttatgagcat	gggatataat	cctcaaagaa	4080
gaactccgct	ataaacaatt	tcaacaagga	gagtcaatgc	tgtgttctgc	tggttggaac	4140
acgtgcctgc	agtcaaacca	ttaaactctt	gcgagctgat	gcgtttattc	tttttggaag	4200
cagcttgaat	ccatcgcatg	atgttaagca	cgtagagaag	ataaaaaatc	agtcatgttc	4260
tgaagaactt	aagatatcc	gattgtactc	agtatgtaca	gttgaagaaa	aagccctgat	4320
tctggctagg	caaaaatatg	ggcaaaaata	agctgtagag	aacctaaacc	gctctctcac	4380
gcacgcactg	ctcatgtggg	gggcgtcata	cttatttgat	aaactggatc	attttcacag	4440
cagtgaactt	ccagattcag	gagtttctat	tgaacaatct	attatggacg	gcgtgattca	4500
tgaattctcg	tccatacttt	cttccaaagg	tggagaagaa	aatgaagtca	agctgtgtct	4560
acttttgtag	gccaaagcat	ctcagggagc	ttcacagcag	gattctactc	tatttggtga	4620
agaccatatt	aagttgtcag	atgaagagag	ttccaaatata	ttttgggtcaa	agctgttggg	4680
gggaaaaaat	cctatgtgga	aatacccttc	agatactccc	caaaggaatc	gaaaacgagt	4740

- 4 -

tcagtatttt	gaggggttctg	aagcgagtc	caaaactggc	gatggtggaa	atgcaaagaa	4800
gcgaaagaag	gcttctgatg	atgtcactga	tccccgggtc	actgatccgc	cagtagatga	4860
tgatgaaaga	aaggcctctg	ggaaggatca	catgggtaaa	atagtttaat	ttctgctccg	4920
atacctctag	tgttcattga	ttatgcaact	actttgctga	ctatctttcc	tacaggggct	4980
ttggagtcac	caaaagtcac	aacactccag	tcacatgta	aatcttctgg	tacagatggg	5040
acattggatg	gaaatgatgc	ttttggcttg	tattctatgg	gcagccatat	ctctggaatc	5100
ccagaggata	tgttagctag	tcaagattgg	gggaaaatac	cggatgaatc	acagaggagg	5160
ctccacactg	ttttaagacc	gaagatggca	aaactttgcc	aagttttgca	tctttcagta	5220
agtggccttt	ttcacctcca	caacttattt	tagccttgca	tatgcttata	tatagctgat	5280
tgcaactgta	gttggtacct	gatttcctgt	tacagccaaa	tgtgagagtt	ttattcttca	5340
actatatcca	tccgtttaag	catattttat	ttcttatatc	tggcttcggt	accaatgcac	5400
tgttaaaaatg	agcaactgct	gcacaaaaca	gtaggtagtt	atgtgcctca	tgtcattcat	5460
tgtttattga	agcaaagaaa	tttctgtcta	ctttacatga	tccatctgtg	ggagtatata	5520
actatatata	accttaggcc	tttgtaacctg	gctgatcaaa	gacatgtcaa	aagtttatct	5580
gttcgctggt	ggtatagaaa	ctaatacagt	gtctgatgct	attttaaggt	agtcttatgt	5640
cttcacatat	tggtataatag	atgtttccgc	tgtcgtgtcc	atatacttct	gtgattatca	5700
cgggtgctccg	tctatcaaaa	ttgtactaaa	aggtattttg	caatgtgtga	ttggttaaca	5760
gattattttg	ttttcaggat	gcttgcacaa	gcatggtcgg	aaattttctc	gaatatgtta	5820
ttgaaaatca	ccgaatctac	gaagagccag	ccactacttt	tcaggcattc	cagatagccc	5880
tggtatgaca	gcatttactt	tgataattta	tgcattgttt	ccttcacat	ctgcctttgt	5940
ttagaatgtc	ctcagaaggc	agcactcctt	tagttttaac	ttccaatca	taggattcaa	6000
atatccatta	actggccttt	gactcgctgca	taatatatga	atagttgaca	tactgaatac	6060
gttggttaata	atgcattttc	agagttggat	tgcagccttg	ttggtaaagc	aaattcttag	6120
ccacaaagaa	tctctggtcc	gtgcaaattc	tgaattagct	ttcaaagtct	ctagagtaga	6180
ggtggattat	atttattcga	tattgtcctg	catgaagagt	ctgttcctgg	agcatacaca	6240
aggtttgcag	ttcgattgct	ttggtactaa	ttctaaacag	tcagtgggta	gcacaaaact	6300
agtaaatgaa	agtctctcag	gggtacagt	gcgtagcgaa	aagattaata	cgaagtcgat	6360
gcgaaatagc	tcagaggatg	aagagtgcac	gactgagaag	agatgtagcc	attatagcac	6420
agcaacaaga	gatatcgaaa	agactattag	tggcataaaa	aagaaataca	agaagcaagt	6480
gcaaaagctt	gtacaagagc	atgaggaaaa	gaaaatggag	ctgttaaata	tgtatgcaga	6540
caagaagcag	aaacttgaaa	ctagtataag	tgtggaagca	gcagtaattc	gtattacctg	6600
ttcacggacc	agtactcaag	tgggtgatct	caaactgctg	gatcataatt	atgaaagaaa	6660
gtttgatgaa	atcaaaagtg	agaaaaatga	atgcctcaaa	agtctggagc	aaatgcacga	6720
ggttgcaaa	aagaagttgg	ctgaggatga	agcctgttgg	attaatcgga	taaagagctg	6780
ggcagctaaa	ttaaaagttt	gtgttcccat	tcaaagtggc	aataacaagc	atttttagtgg	6840
ttcatcaaac	atttcccaaa	atgctcctga	tgtacaaatt	tgcaataatg	ctaactgtga	6900
agctacttac	gctgatacga	attgcatggc	ttccaagggt	aatcaagtgc	cagaagcaga	6960
aaacacatta	ggaaccatgt	cgggtggcag	cactcaacaa	gttcatgaaa	tgggtggatgt	7020
aagaaatgac	gagacaatgg	atgtctcagc	tttgtctcgt	gaacagctta	caaagagcca	7080
gtccaatgag	cacgcttcta	tcactgtgcc	tgagattttg	attcctgctg	actgtcaaga	7140
ggaatttgcg	gccttgaacg	tgcatattgtc	agaagaccag	aattgtgaca	gaataacatc	7200
tgcgcatca	gatgaagatg	tttcatcaag	ggtgccagag	gtatcccagt	cactcgaaaa	7260
tctttctgcc	tcccccgagt	tttctctaaa	tagagaggag	gctttgggta	caacagaaaa	7320
tagaagaaca	agtcattgtg	gttttgatac	tgataacatt	ttggaccagc	agaatagaga	7380
agattgttct	cttgaccaag	agattcctga	cgagttagcg	atgcctgtgc	aacatcttgc	7440
gtctgtggta	gagactaggg	gtgctgctga	atctgatcag	gtacttactg	gccctgtaga	7500
atagttgatg	ccttggttcat	ttaatctttt	ctaagtgtca	ttcttgcttt	cttgaaaata	7560
acgggtagtg	atcagatgtc	tttttttctc	ttattaaatt	cacttttctg	gacagtatgg	7620
tcaagatata	tgctctatgc	cttcttcact	ggctggaaa	caacctgacc	cagcagcaaa	7680
cactgagagc	gaaaatcttg	aagaagcaat	tgagcctcag	tctgctgggt	cagaaacagt	7740
agagactact	gattttgctg	catcacatca	ggtccctatt	gaagactttc	cttttttact	7800
agtttaaagt	tatcaatctg	tgttatgttc	attctaagtt	tccgtgagaa	aaaggtgggg	7860
aaatgtgggt	tctcgttaag	gttttaaact	gactcttttg	agcctgcgcc	agaagcaaat	7920
caagttacat	gtcctttgct	atcttcacgg	actggaaatc	agcctgcgcc	agaagcaaat	7980
attgaaggcc	aaaatatcaa	cacatcagct	gagccccatg	tagcgggtcc	agatgcagta	8040

- 5 -

```

gagagtgggtg attatgcagt aatagatcag gttattgcct taactaaaga caaatgtctt 8100
ttgttggttta aaagtcttac atctttgtaa tgctcgttct ggatatacctg caggaaacaa 8160
tgggtgctca ggatgcatgc tctctgccat ctggatcggg tggaaactcag tctgacctag 8220
gagcaaacat tgaggggtcaa aatgtcacaa cagtggctca acttcccaca gatggatcag 8280
atgcagttgt aaccgggtgga tctcctgtat cagatcaggt acctgcctct gctcaaggac 8340
tttcttatgt gttgggtttaa aggtctagtc cttagtaatg ttgaaactaa gcaaacagtg 8400
gatagtgatc atatggttat ttttgcttgt gaatttaata tttctggaca gtgtgccag 8460
gatgcatctc ctatgccatt atcttcgcct ggaaatcacc ctgatacagc agttaatatc 8520
gagggtttag ataacacatc agtagctgag cctcatataa gtggatcaga tgcattgtgaa 8580
atggaaattt cagaacctgg tccccaagta gagcgggtcaa cctttgcaag tcagtaactg 8640
ccttgggcat ttttaagtat cacctaggtc gacatatgtg attgccaaac agctaacaag 8700
gagatgcctt ttgtgcagat cttttccatg aagggtggcgt ggagcattca gcagggtgtaa 8760
cagctcttgt tccatcactt ctttaacaatg gtacggaaca gattgccgtt caacctgttc 8820
ctcaaatacc tttccctgtg ttcaacgacc cgtttctgca tgaactggag aagttgcgga 8880
gagaatcaga gaactcaaag aagacttttg aagaaaaagt cagtttccct cattaccag 8940
ttacctcttg ttttggttta ttttctagct gccattgac tctcagttgc ttgtgagcag 9000
aatcaatct tgaaagctga actcgagagg aagatggctg aagtacaagc agagtttcga 9060
agaaaatttc atgaggtaga agccgagcat aacaccagaa cgacaaagat agagaaggat 9120
aagaatcttg ttataatgaa caaactgttg gcgaatgcgt tcttgtccaa atgtactgac 9180
aagaaggat ctccctcagg agctccaagg ggtaagtgtc gaataatata gcaaatgggt 9240
tttaaaaata aggcgacgaa gtcataatag cactttttct ccaggtaaaa ttcagcagct 9300
agcacagaga gcagcacaag tgagtgcact gagaaattac attgctcctc agcagcttca 9360
ggcatcttct tttcctgtct ctgctctggg ttcggtcct ctgcaacttc agcaatcatc 9420
atttctgtct cctgggtcgg ctctctgca gcctcaggca tcttcgtttc cttcttcagt 9480
ctctcgtcca tcagcccttc ttctgaattt tgcggtctgt ccaatgcctc agcccagaca 9540
gcctctcata tccaacatag ctccaactcc atcagttact cctgcaacaa atccaggtct 9600
gcgttctcct gcaccacacc taaactcata tagaccatcc tcttcaactc ccgtcgccac 9660
agctactcca acctcgtcag tgctcctca agctttgaca tattcagctg tgtcaattca 9720
gcagcagcaa gaacaacaac cgcaacagag cttgagcagt ggattgcaga gcaacaatga 9780
agtggtttgt ctttctgacg acgagtgacc taagaggaga gatggtagg gtcttagtta 9840
ttgattttta gagagttaat aatagtatat atatattgt ataagtaggt tacctaactc 9900
ctgtcgttaa tctaatttag tgagttagga accgactcgt tggctaagggt ctctcctttt 9960
gaaacgcaac gttctacttt catgtatata aatacagttc gatcacacaa cacaaattga 10020
tgattgaaaa tactactgat ttaactttat agaaaaccca aattatagag cgacaacttt 10080
ataaacatgt caaacttcga agttaaaatt taagacccca taattttaca attatagatt 10140
ttaatactcc aactattttg tgatgttaaa agaagtatcc gagtcttttc tttccagttt 10200
ccccacgtc ccatgactcc cccagccagt agaaaaagcc aaaaaagtaa acaaaaagtc 10260
gttaaaaaag ttaaatataa aaaaaaatag atagttgacg tttactaaag tgatttgaat 10320
tgaacaatt 10329

```

&lt;210&gt; 2

&lt;211&gt; 6571

&lt;212&gt; DNA

<213> *Arabidopsis thaliana*

&lt;220&gt;

&lt;221&gt; CDS

&lt;222&gt; (310)..(6312)

&lt;400&gt; 2

cacaagcatg agtttttctt tccggtaatc gtaaaatcaa aaatcgctcg ctcgagaaac 60

gccggtgcta gaagaggaaa gtaccgtaca taatcctgcg aaccaatttc tegtcttctt 120

- 6 -

caaactcagt ttccgaaac cccaaacacc gcgaggattg catggcctga agaaccactt 180  
 aatcgagaat tgtgctggaa ttctcaaatt ttccctcgcg tttttctttc acactctcgg 240  
 aatcggaat ttccaccaag ctccgtcaag cgatagattc tgacaattac acactttcgc 300  
 gcagtgaat atg aag aaa gat gaa aag att ggt ttg acg ggg aga acc att 351  
     Met Lys Lys Asp Glu Lys Ile Gly Leu Thr Gly Arg Thr Ile  
         1                    5                    10  
 tac acc aga tcc cta gca gct tca att cct gcc tca gtt gaa caa gaa 399  
 Tyr Thr Arg Ser Leu Ala Ala Ser Ile Pro Ala Ser Val Glu Gln Glu  
     15                    20                    25                    30  
 acc cct ggt ttg agg agg tca agc cgg ggg aca cca tct acg aag gta 447  
 Thr Pro Gly Leu Arg Arg Ser Ser Arg Gly Thr Pro Ser Thr Lys Val  
                     35                    40                    45  
 ata act cca gct tct gct act aga aag tca gag aga ctg gct ccc tca 495  
 Ile Thr Pro Ala Ser Ala Thr Arg Lys Ser Glu Arg Leu Ala Pro Ser  
             50                    55                    60  
 cct gct tca gtt tca aaa aag tcc ggt gga atc gtc aag aat tcc aca 543  
 Pro Ala Ser Val Ser Lys Lys Ser Gly Gly Ile Val Lys Asn Ser Thr  
         65                    70                    75  
 cca agt tct ttg cga agg tcc aat agg ggg aag act gaa gta tcc ttg 591  
 Pro Ser Ser Leu Arg Arg Ser Asn Arg Gly Lys Thr Glu Val Ser Leu  
         80                    85                    90  
 cag agt tcc aaa gga tca gat aat tct atc agg aaa gga gat act tca 639  
 Gln Ser Ser Lys Gly Ser Asp Asn Ser Ile Arg Lys Gly Asp Thr Ser  
     95                    100                    105                    110  
 ccg gat att gag cag aga aag gat agt gtt gaa gag tcg aca gat aag 687  
 Pro Asp Ile Glu Gln Arg Lys Asp Ser Val Glu Glu Ser Thr Asp Lys  
             115                    120                    125  
 atc aag cct ata atg tca gcc cga agt tac agg gca ttg ttt aga ggg 735  
 Ile Lys Pro Ile Met Ser Ala Arg Ser Tyr Arg Ala Leu Phe Arg Gly  
         130                    135                    140  
 aag ctc aag gaa tct gag gca tta gtt gat gct tcc cca aat gaa gag 783  
 Lys Leu Lys Glu Ser Glu Ala Leu Val Asp Ala Ser Pro Asn Glu Glu  
         145                    150                    155  
 gaa cta gta gtt gtt ggt tgt tct cgc cgc ata cct gca ggc aat gat 831  
 Glu Leu Val Val Val Gly Cys Ser Arg Arg Ile Pro Ala Gly Asn Asp  
         160                    165                    170  
 gat gtt caa ggt aaa aca gat tgt cca cca cct gca gat gca gga tca 879  
 Asp Val Gln Gly Lys Thr Asp Cys Pro Pro Pro Ala Asp Ala Gly Ser  
     175                    180                    185                    190  
 aaa agg ctg cca gtt gac gaa act agt ttg gac aag ggc act gat ttt 927

- 7 -

Lys	Arg	Leu	Pro	Val	Asp	Glu	Thr	Ser	Leu	Asp	Lys	Gly	Thr	Asp	Phe	
				195					200					205		
cct	ttg	aaa	tca	ggt	acg	gag	acc	gag	aag	ata	gtg	ctt	gat	gca	tcc	975
Pro	Leu	Lys	Ser	Val	Thr	Glu	Thr	Glu	Lys	Ile	Val	Leu	Asp	Ala	Ser	
			210					215					220			
ccc	ata	ggt	gaa	act	ggg	gat	gac	agt	gtt	ata	ggg	tca	cca	tct	gag	1023
Pro	Ile	Val	Glu	Thr	Gly	Asp	Asp	Ser	Val	Ile	Gly	Ser	Pro	Ser	Glu	
		225					230					235				
aat	tta	gag	aca	caa	aag	ctt	caa	gat	ggg	aag	aca	gat	tgt	tca	cca	1071
Asn	Leu	Glu	Thr	Gln	Lys	Leu	Gln	Asp	Gly	Lys	Thr	Asp	Cys	Ser	Pro	
	240					245					250					
cct	gca	aat	gca	gaa	tcg	aaa	acg	ctg	cca	gtt	ggg	gaa	act	agt	tta	1119
Pro	Ala	Asn	Ala	Glu	Ser	Lys	Thr	Leu	Pro	Val	Gly	Glu	Thr	Ser	Leu	
255					260				265						270	
gaa	aaa	gaa	tat	cca	caa	aag	ttt	caa	gat	gat	aac	aca	gat	tgt	cta	1167
Glu	Lys	Glu	Tyr	Pro	Gln	Lys	Phe	Gln	Asp	Asp	Asn	Thr	Asp	Cys	Leu	
			275					280						285		
cca	cct	gca	aat	gca	gaa	tca	aaa	agg	ctg	cca	gtt	ggc	gaa	act	agt	1215
Pro	Pro	Ala	Asn	Ala	Glu	Ser	Lys	Arg	Leu	Pro	Val	Gly	Glu	Thr	Ser	
			290					295					300			
tta	gaa	aag	gac	act	gat	ttt	cct	ttg	aaa	tca	act	acg	gag	act	gga	1263
Leu	Glu	Lys	Asp	Thr	Asp	Phe	Pro	Leu	Lys	Ser	Thr	Thr	Glu	Thr	Gly	
		305					310						315			
aag	atg	gtt	ctt	tat	gca	tcc	ccc	ata	gtt	gaa	act	agg	gat	gac	agc	1311
Lys	Met	Val	Leu	Tyr	Ala	Ser	Pro	Ile	Val	Glu	Thr	Arg	Asp	Asp	Ser	
	320					325					330					
gtt	ata	tgt	tca	cca	tct	aca	aat	tta	gaa	acc	caa	aag	ctt	ctt	gtc	1359
Val	Ile	Cys	Ser	Pro	Ser	Thr	Asn	Leu	Glu	Thr	Gln	Lys	Leu	Leu	Val	
335					340				345						350	
agt	aaa	act	ggc	tta	gaa	acc	gac	ata	gtt	ttg	cct	ttg	aaa	aga	aaa	1407
Ser	Lys	Thr	Gly	Leu	Glu	Thr	Asp	Ile	Val	Leu	Pro	Leu	Lys	Arg	Lys	
			355						360					365		
aga	gac	act	gca	gaa	att	gag	ctg	gat	gca	tgt	gct	aca	gtt	gca	aat	1455
Arg	Asp	Thr	Ala	Glu	Ile	Glu	Leu	Asp	Ala	Cys	Ala	Thr	Val	Ala	Asn	
			370					375					380			
gga	gat	gat	cac	gtt	atg	agt	tct	gat	ggg	gtc	att	cca	tct	cca	tct	1503
Gly	Asp	Asp	His	Val	Met	Ser	Ser	Asp	Gly	Val	Ile	Pro	Ser	Pro	Ser	
		385					390					395				
ggg	tgc	aaa	aat	gat	aat	cga	cct	gaa	atg	tgc	aac	acg	tgt	aaa	aaa	1551
Gly	Cys	Lys	Asn	Asp	Asn	Arg	Pro	Glu	Met	Cys	Asn	Thr	Cys	Lys	Lys	
	400					405						410				

- 8 -

cgg caa aag gtc aac ggt gat tgt caa aat agg agt gtt tgc tcc tgc	1599
Arg Gln Lys Val Asn Gly Asp Cys Gln Asn Arg Ser Val Cys Ser Cys	
415 420 425 430	
att gtc cag cca gtt gaa gaa tct gat aac gtg aca cag gat atg aaa	1647
Ile Val Gln Pro Val Glu Glu Ser Asp Asn Val Thr Gln Asp Met Lys	
435 440 445	
gaa act gga cca gtt acg agc aga gaa tat gag gag aac ggg caa ata	1695
Glu Thr Gly Pro Val Thr Ser Arg Glu Tyr Glu Glu Asn Gly Gln Ile	
450 455 460	
caa cat ggt aaa tca agt gat ccc aaa ttc tat tct tcg gtg tac cca	1743
Gln His Gly Lys Ser Ser Asp Pro Lys Phe Tyr Ser Ser Val Tyr Pro	
465 470 475	
gag tat tgg gtt cct gtg cag cta tca gat gta cag ctg gag caa tac	1791
Glu Tyr Trp Val Pro Val Gln Leu Ser Asp Val Gln Leu Glu Gln Tyr	
480 485 490	
tgt cag act ctc ttc tcc aaa tcc tta tct ctt tct tca ctt tcg aag	1839
Cys Gln Thr Leu Phe Ser Lys Ser Leu Ser Leu Ser Ser Leu Ser Lys	
495 500 505 510	
att gat ctt gga gct cta gaa gaa act ctc aat tct gta aga aaa acc	1887
Ile Asp Leu Gly Ala Leu Glu Glu Thr Leu Asn Ser Val Arg Lys Thr	
515 520 525	
tgt gac cat cca tac gtt atg gat gca tct ttg aaa caa ctg ctc acc	1935
Cys Asp His Pro Tyr Val Met Asp Ala Ser Leu Lys Gln Leu Leu Thr	
530 535 540	
aag aat ctg gag ttg cat gaa atc ctg gat gta gaa att aaa gcg agc	1983
Lys Asn Leu Glu Leu His Glu Ile Leu Asp Val Glu Ile Lys Ala Ser	
545 550 555	
ggg aaa ctt cac ctc ctt gat aaa atg ctt act cat ata aaa aag aat	2031
Gly Lys Leu His Leu Leu Asp Lys Met Leu Thr His Ile Lys Lys Asn	
560 565 570	
ggt tta aaa gca gtt gtc ttc tac cag gca aca caa acc cct gaa ggg	2079
Gly Leu Lys Ala Val Val Phe Tyr Gln Ala Thr Gln Thr Pro Glu Gly	
575 580 585 590	
ctt ctg ctt ggt aat att ctc gaa gat ttt gtg ggt caa aga ttt ggt	2127
Leu Leu Leu Gly Asn Ile Leu Glu Asp Phe Val Gly Gln Arg Phe Gly	
595 600 605	
cca aaa tct tat gag cat ggg ata tat tcc tca aag aag aac tcc gct	2175
Pro Lys Ser Tyr Glu His Gly Ile Tyr Ser Ser Lys Lys Asn Ser Ala	
610 615 620	
ata aac aat ttc aac aag gag agt caa tgc tgt gtt ctg ctg ttg gaa	2223
Ile Asn Asn Phe Asn Lys Glu Ser Gln Cys Cys Val Leu Leu Leu Glu	
625 630 635	

- 9 -

aca cgt gcc tgc agt caa acc att aaa ctc ttg cga gct gat gcg ttt	2271
Thr Arg Ala Cys Ser Gln Thr Ile Lys Leu Leu Arg Ala Asp Ala Phe	
640 645 650	
att ctt ttt gga agc agc ttg aat cca tcg cat gat gtt aag cac gta	2319
Ile Leu Phe Gly Ser Ser Leu Asn Pro Ser His Asp Val Lys His Val	
655 660 665 670	
gag aag ata aaa atc gag tca tgt tct gaa aga act aag ata ttc cga	2367
Glu Lys Ile Lys Ile Glu Ser Cys Ser Glu Arg Thr Lys Ile Phe Arg	
675 680 685	
ttg tac tca gta tgt aca gtt gaa gaa aaa gcc ctg att ctg gct agg	2415
Leu Tyr Ser Val Cys Thr Val Glu Glu Lys Ala Leu Ile Leu Ala Arg	
690 695 700	
caa aat atg cgg caa aat aaa gct gta gag aac cta aac cgc tct ctc	2463
Gln Asn Met Arg Gln Asn Lys Ala Val Glu Asn Leu Asn Arg Ser Leu	
705 710 715	
acg cac gca ctg ctc atg tgg ggg gcg tca tac tta ttt gat aaa ctg	2511
Thr His Ala Leu Leu Met Trp Gly Ala Ser Tyr Leu Phe Asp Lys Leu	
720 725 730	
gat cat ttt cac agc agt gaa act cca gat tca gga gtt tca ttt gaa	2559
Asp His Phe His Ser Ser Glu Thr Pro Asp Ser Gly Val Ser Phe Glu	
735 740 745 750	
caa tct att atg gac ggc gtg att cat gaa ttc tcg tcc ata ctt tct	2607
Gln Ser Ile Met Asp Gly Val Ile His Glu Phe Ser Ser Ile Leu Ser	
755 760 765	
tcc aaa ggt gga gaa gaa aat gaa gtc aag ctg tgt cta ctt ttg gag	2655
Ser Lys Gly Gly Glu Glu Asn Glu Val Lys Leu Cys Leu Leu Leu Glu	
770 775 780	
gcc aag cat gct cag gga act tac agc agt gat tct act cta ttt ggt	2703
Ala Lys His Ala Gln Gly Thr Tyr Ser Ser Asp Ser Thr Leu Phe Gly	
785 790 795	
gaa gac cat att aag ttg tca gat gaa gag agt cca aat ata ttt tgg	2751
Glu Asp His Ile Lys Leu Ser Asp Glu Glu Ser Pro Asn Ile Phe Trp	
800 805 810	
tca aag ctg ttg ggg gga aaa aat cct atg tgg aaa tac cct tca gat	2799
Ser Lys Leu Leu Gly Gly Lys Asn Pro Met Trp Lys Tyr Pro Ser Asp	
815 820 825 830	
act ccc caa agg aat cga aaa cga gtt cag tat ttt gag ggt tct gaa	2847
Thr Pro Gln Arg Asn Arg Lys Arg Val Gln Tyr Phe Glu Gly Ser Glu	
835 840 845	
gcg agt ccc aaa act ggc gat ggt gga aat gca aag aag cga aag aag	2895
Ala Ser Pro Lys Thr Gly Asp Gly Gly Asn Ala Lys Lys Arg Lys Lys	



- 10 -

850	855	860	
gct tct gat gat gtc act gat	ccc cgg gtc act gat	ccg cca gta gat	2943
Ala Ser Asp Asp Val Thr Asp	Pro Arg Val Thr Asp	Pro Pro Val Asp	
865	870	875	
gat gat gaa aga aag gcc tct	ggg aag gat cac atg ggg	gct ttg gag	2991
Asp Asp Glu Arg Lys Ala Ser	Gly Lys Asp His Met Gly	Ala Leu Glu	
880	885	890	
tca cca aaa gtc ata aca ctc	cag tca tca tgt aaa tct tct	ggt aca	3039
Ser Pro Lys Val Ile Thr Leu	Gln Ser Ser Cys Lys Ser Ser	Gly Thr	
895	900	905	910
gat ggt aca ttg gat gga aat	gat gct ttt ggc ttg tat tct	atg ggc	3087
Asp Gly Thr Leu Asp Gly Asn	Asp Ala Phe Gly Leu Tyr Ser	Met Gly	
915	920	925	
agc cat atc tct gga atc cca	gag gat atg tta gct agt	caa gat tgg	3135
Ser His Ile Ser Gly Ile Pro	Glu Asp Met Leu Ala Ser	Gln Asp Trp	
930	935	940	
ggg aaa ata ccg gat gaa tca	cag agg agg ctc cac act	ggt tta aag	3183
Gly Lys Ile Pro Asp Glu Ser	Gln Arg Arg Leu His Thr	Val Leu Lys	
945	950	955	
ccg aag atg gca aaa ctt tgc	caa gtt ttg cat ctt tca	gat gct tgc	3231
Pro Lys Met Ala Lys Leu Cys	Gln Val Leu His Leu Ser	Asp Ala Cys	
960	965	970	
aca agc atg gtc gga aat ttt	ctc gaa tat gtt att gaa	aat cac cga	3279
Thr Ser Met Val Gly Asn Phe	Leu Glu Tyr Val Ile Glu	Asn His Arg	
975	980	985	990
atc tac gaa gag cca gcc act	act ttt cag gca ttc cag	ata gcc ctg	3327
Ile Tyr Glu Glu Pro Ala Thr	Thr Phe Gln Ala Phe Gln	Ile Ala Leu	
995	1000	1005	
agt tgg att gca gcc ttg ttg	gta aag caa att ctt agc	cac aaa gaa	3375
Ser Trp Ile Ala Ala Leu Leu	Val Lys Gln Ile Leu Ser	His Lys Glu	
1010	1015	1020	
tct ctg gtc cgt gca aat tct	gaa tta gct ttc aaa tgc	tct aga gta	3423
Ser Leu Val Arg Ala Asn Ser	Glu Leu Ala Phe Lys Cys	Ser Arg Val	
1025	1030	1035	
gag gtg gat tat att tat tgc	ata ttg tcc tgc atg aag	agt ctg ttc	3471
Glu Val Asp Tyr Ile Tyr Ser	Ile Leu Ser Cys Met Lys	Ser Leu Phe	
1040	1045	1050	
ctg gag cat aca caa ggt ttg	cag ttc gat tgc ttt ggt	act aat tct	3519
Leu Glu His Thr Gln Gly Leu	Gln Phe Asp Cys Phe Gly	Thr Asn Ser	
1055	1060	1065	1070
aaa cag tca gtg gtt agc aca	aaa cta gta aat gaa	agt ctc tca ggg	3567



- 12 -

gtg cca gaa gca gaa aac aca tta gga acc atg tcg ggt ggc agc act	4239
Val Pro Glu Ala Glu Asn Thr Leu Gly Thr Met Ser Gly Gly Ser Thr	
1295                      1300                      1305                      1310	
caa caa gtt cat gaa atg gtg gat gta aga aat gac gag aca atg gat	4287
Gln Gln Val His Glu Met Val Asp Val Arg Asn Asp Glu Thr Met Asp	
1315                      1320                      1325	
gtc tca gct ttg tct cgt gaa cag ctt aca aag agc cag tcc aat gag	4335
Val Ser Ala Leu Ser Arg Glu Gln Leu Thr Lys Ser Gln Ser Asn Glu	
1330                      1335                      1340	
cac gct tct atc act gtg cct gag att ttg att cct gct gac tgt caa	4383
His Ala Ser Ile Thr Val Pro Glu Ile Leu Ile Pro Ala Asp Cys Gln	
1345                      1350                      1355	
gag gaa ttt gcg gcc ttg aac gtg cat ttg tca gaa gac cag aat tgt	4431
Glu Glu Phe Ala Ala Leu Asn Val His Leu Ser Glu Asp Gln Asn Cys	
1360                      1365                      1370	
gac aga ata aca tct gcg gca tca gat gaa gat gtt tca tca agg gtg	4479
Asp Arg Ile Thr Ser Ala Ala Ser Asp Glu Asp Val Ser Ser Arg Val	
1375                      1380                      1385                      1390	
cca gag gta tcc cag tca ctc gaa aat ctt tct gcc tcc ccc gag ttt	4527
Pro Glu Val Ser Gln Ser Leu Glu Asn Leu Ser Ala Ser Pro Glu Phe	
1395                      1400                      1405	
tct cta aat aga gag gag gct ttg gtt aca aca gaa aat aga aga aca	4575
Ser Leu Asn Arg Glu Glu Ala Leu Val Thr Glu Asn Arg Arg Thr	
1410                      1415                      1420	
agt cat gtg ggt ttt gat act gat aac att ttg gac cag cag aat aga	4623
Ser His Val Gly Phe Asp Thr Asp Asn Ile Leu Asp Gln Gln Asn Arg	
1425                      1430                      1435	
gaa gat tgt tct ctt gac caa gag att cct gac gag tta gcg atg cct	4671
Glu Asp Cys Ser Leu Asp Gln Glu Ile Pro Asp Glu Leu Ala Met Pro	
1440                      1445                      1450	
gtg caa cat ctt gcg tct gtg gta gag act agg ggt gct gct gaa tct	4719
Val Gln His Leu Ala Ser Val Val Glu Thr Arg Gly Ala Ala Glu Ser	
1455                      1460                      1465                      1470	
gat cag tat ggt caa gat ata tgt cct atg cct tct tca ctg gct gga	4767
Asp Gln Tyr Gly Gln Asp Ile Cys Pro Met Pro Ser Ser Leu Ala Gly	
1475                      1480                      1485	
aag caa cct gac cca gca gca aac act gag agc gaa aat ctt gaa gaa	4815
Lys Gln Pro Asp Pro Ala Ala Asn Thr Glu Ser Glu Asn Leu Glu Glu	
1490                      1495                      1500	
gca att gag cct cag tct gct ggt tca gaa aca gta gag act act gat	4863
Ala Ile Glu Pro Gln Ser Ala Gly Ser Glu Thr Val Glu Thr Thr Asp	
1505                      1510                      1515	



- 14 -

1730	1735	1740	
ttg cgg aga gaa tca gag aac tca aag aag act ttt gaa gaa aaa aaa			5583
Leu Arg Arg Glu Ser Glu Asn Ser Lys Lys Thr Phe Glu Glu Lys Lys			
1745	1750	1755	
tca atc ttg aaa gct gaa ctc gag agg aag atg gct gaa gta caa gca			5631
Ser Ile Leu Lys Ala Glu Leu Glu Arg Lys Met Ala Glu Val Gln Ala			
1760	1765	1770	
gag ttt cga aga aaa ttt cat gag gta gaa gcc gag cat aac acc aga			5679
Glu Phe Arg Arg Lys Phe His Glu Val Glu Ala Glu His Asn Thr Arg			
1775	1780	1785	1790
acg aca aag ata gag aag gat aag aat ctt gtt ata atg aac aaa ctg			5727
Thr Thr Lys Ile Glu Lys Asp Lys Asn Leu Val Ile Met Asn Lys Leu			
1795	1800	1805	
ttg gcg aat gcg ttc ttg tcc aaa tgt act gac aag aag gta tct ccc			5775
Leu Ala Asn Ala Phe Leu Ser Lys Cys Thr Asp Lys Lys Val Ser Pro			
1810	1815	1820	
tca gga gct cca agg ggt aaa att cag cag cta gca cag aga gca gca			5823
Ser Gly Ala Pro Arg Gly Lys Ile Gln Gln Leu Ala Gln Arg Ala Ala			
1825	1830	1835	
caa gtg agt gca ctg aga aat tac att gct cct cag cag ctt cag gca			5871
Gln Val Ser Ala Leu Arg Asn Tyr Ile Ala Pro Gln Gln Leu Gln Ala			
1840	1845	1850	
tct tct ttt cct gct cct gct ctg gtt tcg gct cct ctg caa ctt cag			5919
Ser Ser Phe Pro Ala Pro Ala Leu Val Ser Ala Pro Leu Gln Leu Gln			
1855	1860	1865	1870
caa tca tca ttt cct gct cct ggt ccg gct cct ctg cag cct cag gca			5967
Gln Ser Ser Phe Pro Ala Pro Gly Pro Ala Pro Leu Gln Pro Gln Ala			
1875	1880	1885	
tct tcg ttt cct tct tca gtc tct cgt cca tca gcc ctt ctt ctg aat			6015
Ser Ser Phe Pro Ser Ser Val Ser Arg Pro Ser Ala Leu Leu Leu Asn			
1890	1895	1900	
ttt gcg gtc tgt cca atg cct cag ccc aga cag cct ctc ata tcc aac			6063
Phe Ala Val Cys Pro Met Pro Gln Pro Arg Gln Pro Leu Ile Ser Asn			
1905	1910	1915	
ata gct cca act cca tca gtt act cct gca aca aat cca ggt ctg cgt			6111
Ile Ala Pro Thr Pro Ser Val Thr Pro Ala Thr Asn Pro Gly Leu Arg			
1920	1925	1930	
tct cct gca cca cac cta aac tca tat aga cca tcc tct tca act ccc			6159
Ser Pro Ala Pro His Leu Asn Ser Tyr Arg Pro Ser Ser Ser Thr Pro			
1935	1940	1945	1950
gtc gcc aca gct act cca acc tcg tca gtg cct cct caa gct ttg aca			6207

Val	Ala	Thr	Ala	Thr	Pro	Thr	Ser	Ser	Val	Pro	Pro	Gln	Ala	Leu	Thr			
				1955						1960						1965		
tat	tca	gct	gtg	tca	att	cag	cag	cag	caa	gaa	caa	caa	ccg	caa	cag		6255	
Tyr	Ser	Ala	Val	Ser	Ile	Gln	Gln	Gln	Gln	Glu	Gln	Gln	Pro	Gln	Gln			
				1970						1975						1980		
agc	ttg	agc	agt	gga	ttg	cag	agc	aac	aat	gaa	gtg	gtt	tgt	ctt	tct		6303	
Ser	Leu	Ser	Ser	Gly	Leu	Gln	Ser	Asn	Asn	Glu	Val	Val	Cys	Leu	Ser			
				1985						1990						1995		
gac	gac	gag	tgacctaaga	ggagagatgg	ttaggggtctt	agttattgat												6352
Asp	Asp	Glu																
			2000															
ttttagagag	ttaataatag	tatatatata	tatgtataag	taggttacct	aatctctgtc												6412	
gttaatctaa	tttagtgagt	caggaaccga	ctcgttggct	aaggtctctc	cttttgaaac												6472	
gcaacgttct	actttcatgt	atataaatac	agtctgatca	cacaacacaa	attgatgatt												6532	
gaaaatacta	ctgatttaac	ttaaaaaaaa	aaaaaaaaaa													6571		
<p>&lt;210&gt; 3</p> <p>&lt;211&gt; 2001</p> <p>&lt;212&gt; PRT</p> <p>&lt;213&gt; Arabidopsis thaliana</p>																		
<p>&lt;400&gt; 3</p> <p>Met Lys Lys Asp Glu Lys Ile Gly Leu Thr Gly Arg Thr Ile Tyr Thr</p> <p>1 5 10 15</p> <p>Arg Ser Leu Ala Ala Ser Ile Pro Ala Ser Val Glu Gln Glu Thr Pro</p> <p>20 25 30</p> <p>Gly Leu Arg Arg Ser Ser Arg Gly Thr Pro Ser Thr Lys Val Ile Thr</p> <p>35 40 45</p> <p>Pro Ala Ser Ala Thr Arg Lys Ser Glu Arg Leu Ala Pro Ser Pro Ala</p> <p>50 55 60</p> <p>Ser Val Ser Lys Lys Ser Gly Gly Ile Val Lys Asn Ser Thr Pro Ser</p> <p>65 70 75 80</p> <p>Ser Leu Arg Arg Ser Asn Arg Gly Lys Thr Glu Val Ser Leu Gln Ser</p> <p>85 90 95</p> <p>Ser Lys Gly Ser Asp Asn Ser Ile Arg Lys Gly Asp Thr Ser Pro Asp</p> <p>100 105 110</p> <p>Ile Glu Gln Arg Lys Asp Ser Val Glu Glu Ser Thr Asp Lys Ile Lys</p> <p>115 120 125</p> <p>Pro Ile Met Ser Ala Arg Ser Tyr Arg Ala Leu Phe Arg Gly Lys Leu</p>																		

- 16 -

130		135		140
Lys Glu Ser Glu Ala Leu Val Asp Ala Ser Pro Asn Glu Glu Glu Leu				
145		150		155
				160
Val Val Val Gly Cys Ser Arg Arg Ile Pro Ala Gly Asn Asp Asp Val				
		165		170
				175
Gln Gly Lys Thr Asp Cys Pro Pro Pro Ala Asp Ala Gly Ser Lys Arg				
		180		185
				190
Leu Pro Val Asp Glu Thr Ser Leu Asp Lys Gly Thr Asp Phe Pro Leu				
		195		200
				205
Lys Ser Val Thr Glu Thr Glu Lys Ile Val Leu Asp Ala Ser Pro Ile				
		210		215
				220
Val Glu Thr Gly Asp Asp Ser Val Ile Gly Ser Pro Ser Glu Asn Leu				
		225		230
				235
				240
Glu Thr Gln Lys Leu Gln Asp Gly Lys Thr Asp Cys Ser Pro Pro Ala				
		245		250
				255
Asn Ala Glu Ser Lys Thr Leu Pro Val Gly Glu Thr Ser Leu Glu Lys				
		260		265
				270
Glu Tyr Pro Gln Lys Phe Gln Asp Asp Asn Thr Asp Cys Leu Pro Pro				
		275		280
				285
Ala Asn Ala Glu Ser Lys Arg Leu Pro Val Gly Glu Thr Ser Leu Glu				
		290		295
				300
Lys Asp Thr Asp Phe Pro Leu Lys Ser Thr Thr Glu Thr Gly Lys Met				
		305		310
				315
				320
Val Leu Tyr Ala Ser Pro Ile Val Glu Thr Arg Asp Asp Ser Val Ile				
		325		330
				335
Cys Ser Pro Ser Thr Asn Leu Glu Thr Gln Lys Leu Leu Val Ser Lys				
		340		345
				350
Thr Gly Leu Glu Thr Asp Ile Val Leu Pro Leu Lys Arg Lys Arg Asp				
		355		360
				365
Thr Ala Glu Ile Glu Leu Asp Ala Cys Ala Thr Val Ala Asn Gly Asp				
		370		375
				380
Asp His Val Met Ser Ser Asp Gly Val Ile Pro Ser Pro Ser Gly Cys				
		385		390
				395
				400
Lys Asn Asp Asn Arg Pro Glu Met Cys Asn Thr Cys Lys Lys Arg Gln				
		405		410
				415
Lys Val Asn Gly Asp Cys Gln Asn Arg Ser Val Cys Ser Cys Ile Val				
		420		425
				430

Gln	Pro	Val	Glu	Glu	Ser	Asp	Asn	Val	Thr	Gln	Asp	Met	Lys	Glu	Thr
		435					440					445			
Gly	Pro	Val	Thr	Ser	Arg	Glu	Tyr	Glu	Glu	Asn	Gly	Gln	Ile	Gln	His
		450				455					460				
Gly	Lys	Ser	Ser	Asp	Pro	Lys	Phe	Tyr	Ser	Ser	Val	Tyr	Pro	Glu	Tyr
465					470					475					480
Trp	Val	Pro	Val	Gln	Leu	Ser	Asp	Val	Gln	Leu	Glu	Gln	Tyr	Cys	Gln
				485					490					495	
Thr	Leu	Phe	Ser	Lys	Ser	Leu	Ser	Leu	Ser	Ser	Leu	Ser	Lys	Ile	Asp
			500					505					510		
Leu	Gly	Ala	Leu	Glu	Glu	Thr	Leu	Asn	Ser	Val	Arg	Lys	Thr	Cys	Asp
		515					520					525			
His	Pro	Tyr	Val	Met	Asp	Ala	Ser	Leu	Lys	Gln	Leu	Leu	Thr	Lys	Asn
		530				535					540				
Leu	Glu	Leu	His	Glu	Ile	Leu	Asp	Val	Glu	Ile	Lys	Ala	Ser	Gly	Lys
545					550					555					560
Leu	His	Leu	Leu	Asp	Lys	Met	Leu	Thr	His	Ile	Lys	Lys	Asn	Gly	Leu
				565					570					575	
Lys	Ala	Val	Val	Phe	Tyr	Gln	Ala	Thr	Gln	Thr	Pro	Glu	Gly	Leu	Leu
			580					585					590		
Leu	Gly	Asn	Ile	Leu	Glu	Asp	Phe	Val	Gly	Gln	Arg	Phe	Gly	Pro	Lys
		595					600					605			
Ser	Tyr	Glu	His	Gly	Ile	Tyr	Ser	Ser	Lys	Lys	Asn	Ser	Ala	Ile	Asn
		610				615					620				
Asn	Phe	Asn	Lys	Glu	Ser	Gln	Cys	Cys	Val	Leu	Leu	Leu	Glu	Thr	Arg
625					630					635					640
Ala	Cys	Ser	Gln	Thr	Ile	Lys	Leu	Leu	Arg	Ala	Asp	Ala	Phe	Ile	Leu
				645					650					655	
Phe	Gly	Ser	Ser	Leu	Asn	Pro	Ser	His	Asp	Val	Lys	His	Val	Glu	Lys
			660					665					670		
Ile	Lys	Ile	Glu	Ser	Cys	Ser	Glu	Arg	Thr	Lys	Ile	Phe	Arg	Leu	Tyr
		675					680					685			
Ser	Val	Cys	Thr	Val	Glu	Glu	Lys	Ala	Leu	Ile	Leu	Ala	Arg	Gln	Asn
		690				695					700				
Met	Arg	Gln	Asn	Lys	Ala	Val	Glu	Asn	Leu	Asn	Arg	Ser	Leu	Thr	His
705					710					715					720



- 18 -

Ala Leu Leu Met Trp Gly Ala Ser Tyr Leu Phe Asp Lys Leu Asp His  
 725 730 735  
 Phe His Ser Ser Glu Thr Pro Asp Ser Gly Val Ser Phe Glu Gln Ser  
 740 745 750  
 Ile Met Asp Gly Val Ile His Glu Phe Ser Ser Ile Leu Ser Ser Lys  
 755 760 765  
 Gly Gly Glu Glu Asn Glu Val Lys Leu Cys Leu Leu Leu Glu Ala Lys  
 770 775 780  
 His Ala Gln Gly Thr Tyr Ser Ser Asp Ser Thr Leu Phe Gly Glu Asp  
 785 790 795 800  
 His Ile Lys Leu Ser Asp Glu Glu Ser Pro Asn Ile Phe Trp Ser Lys  
 805 810 815  
 Leu Leu Gly Gly Lys Asn Pro Met Trp Lys Tyr Pro Ser Asp Thr Pro  
 820 825 830  
 Gln Arg Asn Arg Lys Arg Val Gln Tyr Phe Glu Gly Ser Glu Ala Ser  
 835 840 845  
 Pro Lys Thr Gly Asp Gly Gly Asn Ala Lys Lys Arg Lys Lys Ala Ser  
 850 855 860  
 Asp Asp Val Thr Asp Pro Arg Val Thr Asp Pro Pro Val Asp Asp Asp  
 865 870 875 880  
 Glu Arg Lys Ala Ser Gly Lys Asp His Met Gly Ala Leu Glu Ser Pro  
 885 890 895  
 Lys Val Ile Thr Leu Gln Ser Ser Cys Lys Ser Ser Gly Thr Asp Gly  
 900 905 910  
 Thr Leu Asp Gly Asn Asp Ala Phe Gly Leu Tyr Ser Met Gly Ser His  
 915 920 925  
 Ile Ser Gly Ile Pro Glu Asp Met Leu Ala Ser Gln Asp Trp Gly Lys  
 930 935 940  
 Ile Pro Asp Glu Ser Gln Arg Arg Leu His Thr Val Leu Lys Pro Lys  
 945 950 955 960  
 Met Ala Lys Leu Cys Gln Val Leu His Leu Ser Asp Ala Cys Thr Ser  
 965 970 975  
 Met Val Gly Asn Phe Leu Glu Tyr Val Ile Glu Asn His Arg Ile Tyr  
 980 985 990  
 Glu Glu Pro Ala Thr Thr Phe Gln Ala Phe Gln Ile Ala Leu Ser Trp  
 995 1000 1005  
 Ile Ala Ala Leu Leu Val Lys Gln Ile Leu Ser His Lys Glu Ser Leu

- 19 -

1010	1015	1020
Val Arg Ala Asn Ser Glu Leu Ala Phe Lys Cys Ser Arg Val Glu Val 025 1030 1035 1040		
Asp Tyr Ile Tyr Ser Ile Leu Ser Cys Met Lys Ser Leu Phe Leu Glu 1045 1050 1055		
His Thr Gln Gly Leu Gln Phe Asp Cys Phe Gly Thr Asn Ser Lys Gln 1060 1065 1070		
Ser Val Val Ser Thr Lys Leu Val Asn Glu Ser Leu Ser Gly Ala Thr 1075 1080 1085		
Val Arg Asp Glu Lys Ile Asn Thr Lys Ser Met Arg Asn Ser Ser Glu 1090 1095 1100		
Asp Glu Glu Cys Met Thr Glu Lys Arg Cys Ser His Tyr Ser Thr Ala 1105 1110 1115 1120		
Thr Arg Asp Ile Glu Lys Thr Ile Ser Gly Ile Lys Lys Lys Tyr Lys 1125 1130 1135		
Lys Gln Val Gln Lys Leu Val Gln Glu His Glu Glu Lys Lys Met Glu 1140 1145 1150		
Leu Leu Asn Met Tyr Ala Asp Lys Lys Gln Lys Leu Glu Thr Ser Lys 1155 1160 1165		
Ser Val Glu Ala Ala Val Ile Arg Ile Thr Cys Ser Arg Thr Ser Thr 1170 1175 1180		
Gln Val Gly Asp Leu Lys Leu Leu Asp His Asn Tyr Glu Arg Lys Phe 1185 1190 1195 1200		
Asp Glu Ile Lys Ser Glu Lys Asn Glu Cys Leu Lys Ser Leu Glu Gln 1205 1210 1215		
Met His Glu Val Ala Lys Lys Lys Leu Ala Glu Asp Glu Ala Cys Trp 1220 1225 1230		
Ile Asn Arg Ile Lys Ser Trp Ala Ala Lys Leu Lys Val Cys Val Pro 1235 1240 1245		
Ile Gln Ser Gly Asn Asn Lys His Phe Ser Gly Ser Ser Asn Ile Ser 1250 1255 1260		
Gln Asn Ala Pro Asp Val Gln Ile Cys Asn Asn Ala Asn Val Glu Ala 1265 1270 1275 1280		
Thr Tyr Ala Asp Thr Asn Cys Met Ala Ser Lys Val Asn Gln Val Pro 1285 1290 1295		
Glu Ala Glu Asn Thr Leu Gly Thr Met Ser Gly Gly Ser Thr Gln Gln 1300 1305 1310		



- 21 -

Asn Ile Glu Gly Gln Asn Val Thr Thr Val Ala Gln Leu Pro Thr Asp  
 1605 1610 1615  
 Gly Ser Asp Ala Val Val Thr Gly Gly Ser Pro Val Ser Asp Gln Cys  
 1620 1625 1630  
 Ala Gln Asp Ala Ser Pro Met Pro Leu Ser Ser Pro Gly Asn His Pro  
 1635 1640 1645  
 Asp Thr Ala Val Asn Ile Glu Gly Leu Asp Asn Thr Ser Val Ala Glu  
 1650 1655 1660  
 Pro His Ile Ser Gly Ser Asp Ala Cys Glu Met Glu Ile Ser Glu Pro  
 665 1670 1675 1680  
 Gly Pro Gln Val Glu Arg Ser Thr Phe Ala Asn Leu Phe His Glu Gly  
 1685 1690 1695  
 Gly Val Glu His Ser Ala Gly Val Thr Ala Leu Val Pro Ser Leu Leu  
 1700 1705 1710  
 Asn Asn Gly Thr Glu Gln Ile Ala Val Gln Pro Val Pro Gln Ile Pro  
 1715 1720 1725  
 Phe Pro Val Phe Asn Asp Pro Phe Leu His Glu Leu Glu Lys Leu Arg  
 1730 1735 1740  
 Arg Glu Ser Glu Asn Ser Lys Lys Thr Phe Glu Glu Lys Lys Ser Ile  
 745 1750 1755 1760  
 Leu Lys Ala Glu Leu Glu Arg Lys Met Ala Glu Val Gln Ala Glu Phe  
 1765 1770 1775  
 Arg Arg Lys Phe His Glu Val Glu Ala Glu His Asn Thr Arg Thr Thr  
 1780 1785 1790  
 Lys Ile Glu Lys Asp Lys Asn Leu Val Ile Met Asn Lys Leu Leu Ala  
 1795 1800 1805  
 Asn Ala Phe Leu Ser Lys Cys Thr Asp Lys Lys Val Ser Pro Ser Gly  
 1810 1815 1820  
 Ala Pro Arg Gly Lys Ile Gln Gln Leu Ala Gln Arg Ala Ala Gln Val  
 825 1830 1835 1840  
 Ser Ala Leu Arg Asn Tyr Ile Ala Pro Gln Gln Leu Gln Ala Ser Ser  
 1845 1850 1855  
 Phe Pro Ala Pro Ala Leu Val Ser Ala Pro Leu Gln Leu Gln Gln Ser  
 1860 1865 1870  
 Ser Phe Pro Ala Pro Gly Pro Ala Pro Leu Gln Pro Gln Ala Ser Ser  
 1875 1880 1885  
 Phe Pro Ser Ser Val Ser Arg Pro Ser Ala Leu Leu Leu Asn Phe Ala

- 22 -

1890				1895				1900							
Val	Cys	Pro	Met	Pro	Gln	Pro	Arg	Gln	Pro	Leu	Ile	Ser	Asn	Ile	Ala
905					1910					1915					1920
Pro	Thr	Pro	Ser	Val	Thr	Pro	Ala	Thr	Asn	Pro	Gly	Leu	Arg	Ser	Pro
				1925					1930					1935	
Ala	Pro	His	Leu	Asn	Ser	Tyr	Arg	Pro	Ser	Ser	Ser	Thr	Pro	Val	Ala
			1940						1945				1950		
Thr	Ala	Thr	Pro	Thr	Ser	Ser	Val	Pro	Pro	Gln	Ala	Leu	Thr	Tyr	Ser
		1955					1960						1965		
Ala	Val	Ser	Ile	Gln	Gln	Gln	Gln	Glu	Gln	Gln	Pro	Gln	Gln	Ser	Leu
	1970					1975					1980				
Ser	Ser	Gly	Leu	Gln	Ser	Asn	Asn	Glu	Val	Val	Cys	Leu	Ser	Asp	Asp
985					1990					1995					2000
Glu															

```
<210> 4
<211> 21
<212> DNA
<213> Artificial Sequence
```

<220>  
<223> Description of Artificial Sequence: Synthetic  
Oligonucleotide

```
<400> 4
catctacggc aatgtaccag c
```

<210> 5  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Oligonucleotide

<400> 5  
gatgggaatt ggctgagtgg c 21

<210> 6  
<211> 21  
<212> DNA  
<213> Artificial Sequence

- 23 -

&lt;220&gt;

<223> Description of Artificial Sequence:Synthetic  
Oligonucleotide

&lt;400&gt; 6

cagttccaaa cgtaaaacgg c

21

&lt;210&gt; 7

&lt;211&gt; 15

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence:Synthetic  
Oligonucleotide

&lt;400&gt; 7

ntcgastwts gwgtt

15

&lt;210&gt; 8

&lt;211&gt; 16

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence:Synthetic  
Oligonucleotide

&lt;400&gt; 8

ngtcgaswga nawgaa

16

&lt;210&gt; 9

&lt;211&gt; 16

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence:Synthetic  
Oligonucleotide

&lt;400&gt; 9

wgtgnagwan canaga

16

&lt;210&gt; 10

&lt;211&gt; 16

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Description of Artificial Sequence:Synthetic

- 24 -

## Oligonucleotide

<400> 10  
wggwancwga wangca 16

<210> 11  
<211> 16  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence:Synthetic  
Oligonucleotide

<400> 11  
wcgwwgawca ngncga 16

<210> 12  
<211> 16  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence:Synthetic  
Oligonucleotide

<400> 12  
wgcnagtnag wanaag 16

<210> 13  
<211> 16  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence:Synthetic  
Oligonucleotide

<400> 13  
awgcangncw ganata 16

<210> 14  
<211> 24  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence:Synthetic  
Oligonucleotide

<400> 14

24

### <213> Artificial Sequence

<223> Description of Artificial Sequence:Synthetic Oligonucleotide

25

<213> Artificial Sequence

<223> Description of Artificial Sequence:Synthetic  
Oligonucleotide

24

### <213> Artificial Sequence

<223> Description of Artificial Sequence:Synthetic  
Oligonucleotide

25

<213> Artificial Sequence

<223> Description of Artificial Sequence:Synthetic  
Oligonucleotide

25



- 26 -

<210> 19  
<211> 25  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence:Synthetic  
Oligonucleotide

<400> 19  
gctctttgta agctgttcac gagac 25

<210> 20  
<211> 24  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence:Synthetic  
Oligonucleotide

<400> 20  
tcgcatgatg ttaagcacgt agag 24

<210> 21  
<211> 25  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence:Synthetic  
Oligonucleotide

<400> 21  
gagtactggg ccgtgaacag gtaat 25

<210> 22  
<211> 25  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence:Synthetic  
Oligonucleotide

<400> 22  
atgcttgac aagcatgggc ggaaa 25

<210> 23  
<211> 25  
<212> DNA

- 27 -

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence:Synthetic  
Oligonucleotide

&lt;400&gt; 23

tgcaacatcg tgcatttgct ccaga

25

&lt;210&gt; 24

&lt;211&gt; 25

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence:Synthetic  
Oligonucleotide

&lt;400&gt; 24

cacaagcatg agtttttctt tccgg

25

&lt;210&gt; 25

&lt;211&gt; 25

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence:Synthetic  
Oligonucleotide

&lt;400&gt; 25

ctgactttct agtagcagaa gctgg

25

&lt;210&gt; 26

&lt;211&gt; 519

&lt;212&gt; DNA

&lt;213&gt; Brassica oleracea

&lt;220&gt;

&lt;223&gt; seq1-23

&lt;400&gt; 26

```

gaattcctgn nttacggcat ccttaataga ctgttcaa at ggaactcctg aacctggggt 60
tccactccca tggagtggt ccagcttata aaataaatat gatgcccc acatgagcaa 120
tgcattgtgt agaggacggt ttaggttctc tagaggctta ttttgctag caagaatcag 180
gggtttttct tcaactgtaa aactgagta caaccggaaa atcttagttc tttcagaaca 240
cgactcaacc tttatcttct ctaagagctt aacgtcatgc gatggattca ggctgcttcc 300
aaaaagtata aaagactcag cgcgtaagag tttaattgctt tgactacagg cacgtatttc 360
cagcagcaga ataaaacact cactctcctt gttgaaattg tttatagcgt tcttcttcga 420
gaggcagacc ccatgctcat aggaattttg accaaatctt tgcacagaa aatcttcgag 480
aatattacca agcagaagcc cctcagggct atgtattgc 519

```

- 28 -

<210> 27  
 <211> 419  
 <212> DNA  
 <213> Brassica oleracea

<220>  
 <223> seq1-27

<400> 27  
 gaattcagga tcaaaagggt tgccggttg agaaactggt ttagagaaag gctctgattt 60  
 tcctgtggaa gtaactaagg atatagagaa gacagtgggt gattcatccc ccatggttga 120  
 aactgaggat ggcagtgtta taggttcacc atccgagaat ccagaaccac aaaagcttcg 180  
 tgacagtga actagcttg aaaccgatat agacttggct ctgaaaagaa aaagagacac 240  
 tgcagaaatt gtgatggat catgtacaaa tgcagatgac cgcattatga gtactgatgg 300  
 ggttattcct tttccaccg tgtgcacaaa tattaatcaa cccgaaagggt gtggcacatg 360  
 tcaaaaacgg caaaagtaag aatttccgac tgttgtctgt cgttttgaaa ccatttgcc 419

<210> 28  
 <211> 467  
 <212> DNA  
 <213> Brassica oleracea

<220>  
 <223> seq1-43

<400> 28  
 gaattctcgt ccatactttc ttccgatggt ggagaagaaa atgaaggcaa gctgtgtcta 60  
 cttttggaag ccaagcatgc tcagggaagt tacagcactg atgctactct atttggtgaa 120  
 gaacatgtca agttatcaga tgaaagtcca aatatgtttt ggtcaaagct gttgagtggg 180  
 aagaacccta tgtggaaata ctgttcggat actcctcaaa ggagtcgaaa aagagtacgg 240  
 catcttcagg gctatgagga gactaccaaa gttggcaatg gcggaaactt aaagaagaaa 300  
 aagaaggctt cagatgatgt cacagtagat aacgctgaga gaaaagcctc tggaaaggat 360  
 cacatgggta aaacagttca ctctctgctc ctttacctct agtggttcatt gaatgttcca 420  
 ttacttttgc ttactatctt tccttcaggg catttgagat caccaaa 467

<210> 29  
 <211> 490  
 <212> DNA  
 <213> Brassica oleracea

<220>  
 <223> seq1-47

<400> 29  
 gaattcagct tttaaaactg atctctgctc acagataatt taagagtcag tgaaaattga 60  
 gataaaacga accaaaactg gaggtaacag atactctgag aacaactaac cttttcttca 120  
 taagtcttct ttgtgttctc tgattctctc cgagcttct ccagttcatg ctgaaatggg 180  
 tcaactgaaca cagggaaagg tacttgagga acaggtggag tggcattctg tcccgtagca 240  
 ttgttaagct gtgaagaaac aggagctggt acacctgctg gaggtccac aacaccttca 300  
 tcgacaacgt ctgcgtaaaa ggtattacca gattgtcagt ttctctggca aacacatacy 360  
 ttatacttaa atgcaaaaga gcagttactg acttgcaaag gttggttggt ctacttgagc 420

- 29 -

atcaggttct gctacttcca tttcacatgc ttctgatcca gttgtgcgag ggcagccat 480  
 tgttgtgttg 490

<210> 30  
 <211> 515  
 <212> DNA  
 <213> Brassica oleracea

<220>  
 <223> 2-33

<400> 30  
 tctagagaag aggtggatta tgtatattct tttctgtact gcatgaagag tctattcgtg 60  
 gggcgcacac aagggtttcca agaaaagggg gaagaatgca tggctgagaa aagaggtagc 120  
 cattatagct cagtaaccaa ggatgttgaa aagactatta gcgacatcaa aaagaaatgc 180  
 agtaagagcc tgcataagct tgtacaaacc ctcgaggaag aaaagatgga cctgatgaat 240  
 aggaatgctg tcaagaagca ggaacttcag aattgtaaaa aggtggaagc atcatttatt 300  
 cgtgtcacct attcaggat aaatactcag agcttacatg atgctctcca acggctggaa 360  
 tgtacttttg aaagaaagtt tgatgatctc aaaggagagt tggatgaatg ccttgaaagt 420  
 ttagagcaaa taaacgaggc tggaaagaag aagttggctg aagatgaagc ctgttggaat 480  
 agtcggatag agaaatgggc acgagctgaa ttaag 515

<210> 31  
 <211> 574  
 <212> DNA  
 <213> Brassica oleracea

<220>  
 <223> seq2-37

<400> 31  
 tctagaccaa actattaaac gctaaacata agaagattag atcactcgtc atcagagaga 60  
 cagaccacat cattgtcct ctgcaatcca ctcccaagt tctgtggttg ttcttgctgc 120  
 tgaataaacg catttgaata tggtaaaggg ttggagatga gaggttgtct tggttgaggc 180  
 attgtgcagt acggagccga agcagtatga ttctcagtg cgcttacttg tgttgctctc 240  
 tgtgttagct gctggattct aactggagaa agaaaaaag aaaaaaagg tgttattatg 300  
 acttcataac cttatatctt taaaaaaca ttatgcttct attattcgaa cacttgccca 360  
 ttggagttgc tgctgaggaa tgagaggaga ttctgctcgt acatttagac aagaacgcac 420  
 tcgacaacag cttgttcttt ataacaagat tcttcctcgt ctgtaacttc gtctttctgg 480  
 ctgcatgtac agcttgatc tcatgaaact ttctctgata ctcttcttgt aattcagcta 540  
 tcttcttctc gaatttagct ttcaagactg cttt 574

<210> 32  
 <211> 466  
 <212> DNA  
 <213> Brassica oleracea

<220>  
 <223> seq2-53

<400> 32  
 tctagattgt aattttaaat ttacaacaaa ttttgaaagg gtcagcgatg agtttgcaaa 60

tctccgtggt	tctccagca	ttgtccagcc	agtccaagaa	cctgatcact	tggcacaggt	120
tggttttcttc	ttgctttact	ttggacacct	gtttaatat	ggcctgtcaa	attacttat	180
ccttttactt	ctaaactgca	aattctggtc	tgcattgcat	tgtgatatga	aggatatctgg	240
acccgcttca	agcagagact	atgggggagga	caggcagaat	atgcaacaag	ataaaatcaca	300
tgaccgaaag	ttgtcatoga	tgtatccaga	gtattgggtt	ccagtgagc	tatcagatgt	360
cagacatagag	caatactgtc	ggactctctt	ctccaaatct	tcattctctt	cttcgctgtc	420
gaggactgat	cctgttccag	ctcttgaaca	aactctcagt	tctgta		466

<210> 33

<211> 417

<212> DNA

<213> Brassica oleracea

 $\langle 220 \rangle$ 

<223> seq2-57

<400> 33

tctagagcaa	ttgaaaccta	attccgattt	tgcgcggggcc	agagattctt	cacggttgaa	60
cttttgctta	acgaaagaga	ctgcaatcca	aatctggaag	tgcattatta	agaacgtatt	120
cagcaatatt	cataaattat	gcaacaatca	aaggccttac	gttgtggcct	acaaagcatg	180
gattttgtta	gatattagta	gctagtctaa	ttcaagcaat	taatggaagt	ttctatccta	240
tgactggaaa	gttaaacatt	cccacaaaag	cagtgatgcc	acagatgatg	tgcagaataa	300
atgcatabac	tatggaagtg	aatgtctatc	taccacagct	atctggaagg	cctgcaatgt	360
tgtagctggc	tctttgcaga	cacggtggtt	gtcaataata	tattcaagaa	cttttttc	417

# Gene involved in epigenetic gene silencing

The present invention relates to DNA which encodes proteins that control gene silencing, and particularly the silencing of plant genes.

The loss of expression of previously active genes in plants, also referred to as gene silencing, is observed in response to developmental, environmental or unknown signals. It occurs at a frequency higher than that of mutations, yet it is markedly stable during somatic transmission. Gene silencing, initially perceived as an unwanted source of instability of transgene expression, is now regarded as a molecular tool to intentionally regulate gene expression.

It appears that chromosomal position or structure of the affected loci are factors determining the frequency and strength of silencing. Inactivation seems to preferentially affect genes present in multiple copies and is thought to be a consequence of sequence redundancy. Many examples of homology-dependent gene silencing have been reported. Closer analysis has allowed the classification of silencing events according to the relative position of the affected loci (*cis*, *trans*, allelic, ectopic), the origin of the affected genes (endogenous or transgenic), and the level of interaction (transcriptional or post-transcriptional). While post-transcriptional silencing seems to mainly involve the formation of aberrant RNA molecules and is occasionally, but not necessarily, accompanied by DNA methylation, silencing interfering with transcription initiation is more strictly correlated with hypermethylation of the DNA and possibly with alteration of chromatin structure at the silent loci. It is, however, not clear whether these molecular events are a prerequisite for gene silencing or a consequence of the silent state.

In the case of transcriptional silencing, the inactive state of silenced genes is stably transmitted through mitotic and meiotic divisions. As in other organisms, trans-acting modifier loci are assumed to be responsible for the stability of the inactive state of the silenced genes. Mutations in such loci resulting in mutated proteins are expected to result in reduced gene silencing and reactivation of previously silent loci by interfering with the maintenance of the silent state, or by a failure to recognize sequence redundancy. It has been reported that mutations in the DDM1 gene of *Arabidopsis thaliana* release

- 2 -

transcriptional gene silencing and that this genes encodes a SWI2/SNF2-like protein involved in chromatin remodeling. However, mutation of the DDM1 gene causes severe pleiotropic effects. Therefore, to be able to modify such effects making use of gene technology, it is necessary to identify further specific modifier loci and characterize the corresponding wild-type and mutant proteins. It is the main objective of the present invention to provide DNA comprising an open reading frame encoding such a protein.

Trans-acting modifier loci according to the present invention can be identified by T-DNA insertion mutagenesis as described in Example 1 for an Arabidopsis line carrying a heritably inactivated, methylated hygromycin resistance gene. A mutation of a silencing modifier locus results in release of silencing of the hygromycin resistance gene and restores hygromycin resistance. Plants homozygous for the silent resistance gene are subjected to transformation with a selectable marker gene different from the hygromycin resistance gene, which is under the control of the T-DNA 1'-2' dual promoter. Transformants are selected and their progeny screened for hygromycin resistance. The mutant phenotype (hygromycin resistance) is screened for genetic co-segregation with a specific T-DNA insert. Cloning of the tagged gene using routine methods of recombinant DNA technology allows to characterize the mutant and wild-type DNA sequence of the silencing modifier locus as well as the encoded protein.

Within the context of the present invention reference to a gene is to be understood as reference to a DNA coding sequence associated with regulatory sequences, which allow transcription of the coding sequence into RNA such as mRNA, rRNA, tRNA, snRNA, sense RNA or antisense RNA. Examples of regulatory sequences are promoter sequences, 5' and 3' untranslated sequences, introns, and termination sequences.

A promoter is understood to be a DNA sequence initiating transcription of an associated DNA sequence, and may also include elements that act as regulators of gene expression such as activators, enhancers, or repressors.

Expression of a gene refers to its transcription into RNA or its transcription and subsequent translation into protein within a living cell. In the case of antisense constructs expression refers to the transcription of the antisense DNA only.

The term transformation of cells designates the introduction of nucleic acid into a host cell, particularly the stable integration of a DNA molecule into the genome of said cell.

In a preferred embodiment of the present invention at least one of the component sequences R<sub>1</sub> or R<sub>3</sub> comprises one or more additional component sequences with a length of at least 50 amino acids and at least 60% identical to an aligned component sequence of SEQ ID NO: 3. Specific examples of such additional component sequences are component sequences of SEQ ID NO: 3 represented by the following range of amino acids:



- 4 -

- 420 - 525 (corresponding to exons 3 and 4);
- 444 - 525 (corresponding to exon 4);
- 526 - 583 (corresponding to exon 5);
- 892 - 971 (corresponding to exon 7);
- 892 - 1006 (corresponding to exons 7 and 8);
- 1473 - 1524 (corresponding to exon 10);
- 1525 - 1576 (corresponding to exon 11);
- 1577 - 1631 (corresponding to exon 12);
- 1632 - 1690 (corresponding to exons 13);
- 1692 - 1757 (corresponding to exons 14); and
- 1758 - 1827 (corresponding to exons 15).

Particularly preferred embodiments of the DNA according to the present invention encode a protein having a component sequence defined by amino acids 478-490, 584-600, 617-630, 654-668, 676-690, 718-734, 776-788, 1222-1233, 1738-1749 or 1761-1770 of SEQ ID NO: 3. Preferably, the encoded protein comprises at least two, three or more different representatives of said component sequences. Specific examples of said embodiments encode a protein characterized by the amino acid sequence of SEQ ID NO: 3, an allelic amino acid sequence having amino acid residue K instead of M at position 705 of SEQ ID NO: 3, or an amino acid residue D instead of E at position 1219 of SEQ ID NO: 3.

Dynamic programming algorithms yield different kinds of alignments. In general there exist two approaches towards sequence alignment. Algorithms as proposed by Needleman & Wunsch and by Sellers align the entire length of two sequences providing a global alignment of the sequences. The Smith-Waterman algorithm on the other hand yields local alignments. A local alignment aligns the pair of regions within the sequences that are most similar given the choice of scoring matrix and gap penalties. This allows a database search to focus on the most highly conserved regions of the sequences. It also allows similar domains within sequences to be identified. To speed up alignments using the Smith-Waterman algorithm both BLAST (Basic Local Alignment Search Tool) and FASTA place additional restrictions on the alignments.

Within the context of the present invention alignments are conveniently performed using BLAST, a set of similarity search programs designed to explore all of the available

- 5 -

sequence databases regardless of whether the query is protein or DNA. Version BLAST 2.0 (Gapped BLAST) of this search tool has been made publicly available on the internet (currently <http://www.ncbi.nlm.nih.gov/BLAST/>). It uses a heuristic algorithm which seeks local as opposed to global alignments and is therefore able to detect relationships among sequences which share only isolated regions. The scores assigned in a BLAST search have a well-defined statistical interpretation. Particularly useful within the scope of the present invention are the blastp program allowing for the introduction of gaps in the local sequence alignments and the PSI-BLAST program, both programs comparing an amino acid query sequence against a protein sequence database, as well as a blastp variant program allowing local alignment of two sequences only. Said programs are preferably run with optional parameters set to the default values.

Sequence alignments using BLAST can also take into account whether the substitution of one amino acid for another is likely to conserve the physical and chemical properties necessary to maintain the structure and function of the protein or is more likely to disrupt essential structural and functional features of a protein. Such sequence similarity is quantified in terms of a percentage of "positive" amino acids, as compared to the percentage of identical amino acids and can help assigning a protein to the correct protein family in border-line cases.

Sequence alignments using such computer programs reveal the presence of an ATP/GTP-binding motif A (amino acids 460 to 467 in SEQ ID NO:3), the consensus sequence of which is (Ala/Gly)XaaXaaXaaXaaGlyLys(Ser/Thr), wherein (Ala/Gly) indicates Ala or Gly, Xaa indicates any naturally occurring amino acid and (Ser/Thr) indicates Ser or Thr. Alignment additionally reveals a region (amino acid position 479 to 719 in SEQ ID: 3), similar to part of the ATPase/helicase domain of proteins in the SWI2/SNF2 family which are involved in chromatin remodeling but no significant overall sequence identity with known proteins.

Specific examples of DNA according to the present invention are described in SEQ ID NO: 1 and SEQ ID NO: 2 encoding an Arabidopsis protein described in SEQ ID NO: 3. Stretches of SEQ ID NO: 3 having 50 to 500 amino acids length can show between 20 and 50% sequence identity to stretches of known protein sequences after alignment. Overall alignments of SEQ ID NO: 3, however, result in sequence identities lower than 30%. Thus,

the present invention defines a new protein family the members of which are characterized by an amino acid sequence comprising a component sequence of at least 150 amino acid residues having 40% or more identity with an aligned component sequence of SEQ ID NO: 3. Preferably the amino acid sequence identity is higher than 50% or even higher than 55%.

DNA encoding proteins belonging to the new protein family according to the present invention can be isolated from monocotyledonous and dicotyledonous plants. Preferred sources are corn, sugarbeet, sunflower, winter oilseed rape, soybean, cotton, wheat, rice, potato, broccoli, cauliflower, cabbage, cucumber, sweet corn, daikon, garden beans, lettuce, melon, pepper, squash, tomato, or watermelon. However, they can also be isolated from mammalian sources such as mouse or human tissues. The following general method, can be used, which the person skilled in the art knows to adapt to the specific task. A single stranded fragment of SEQ ID NO: 1 or SEQ ID NO: 2 consisting of at least 15, preferably 20 to 30 or even more than 100 consecutive nucleotides is used as a probe to screen a DNA library for clones hybridizing to said fragment. The factors to be observed for hybridization are described in Sambrook et al, Molecular cloning: A laboratory manual, Cold Spring Harbor Laboratory Press, chapters 9.47-9.57 and 11.45-11.49, 1989. Hybridizing clones are sequenced and DNA of clones comprising a complete coding region encoding a protein characterized by an amino acid sequence comprising a component sequence of at least 150 amino acid residues having 40% or more sequence identity to SEQ ID NO: 3 is purified. Said DNA can then be further processed by a number of routine recombinant DNA techniques such as restriction enzyme digestion, ligation, or polymerase chain reaction analysis.

The disclosure of SEQ ID NO: 1 and SEQ ID NO: 2 enables a person skilled in the art to design oligonucleotides for polymerase chain reactions which attempt to amplify DNA fragments from templates comprising a sequence of nucleotides characterized by any continuous sequence of 15 and preferably 20 to 30 or more basepairs in SEQ ID NO: 1 or SEQ ID NO: 2. Said nucleotides comprise a sequence of nucleotides which represents 15 and preferably 20 to 30 or more basepairs of SEQ ID NO: 1 or SEQ ID NO: 2. Polymerase chain reactions performed using at least one such oligonucleotide and their amplification products constitute another embodiment of the present invention.

Selfed seeds (T2 families) are collected from individual transformants. Prior to screening for revertants of the silenced phenotype, seeds are dried for one week at room temperature and cold-treated at 4°C for a minimum of one week. Pooled aliquots of approximately 1000 seeds (consisting of 50 seeds from 20 T2 families) are surface-sterilized twice (with 5% sodium hypochlorite containing 0.1% Tween 80) for 7 min and washed with sterile double-distilled water. For selection, each aliquot is plated on 14-cm Petri dishes containing 75 ml germination medium (according to Masson et al, Plant J 2: 829-933, 1992) solidified with 0.8% agar and containing 10 mg/l hygromycin B (Calbiochem). To ensure equal distribution during sowing, seeds are mixed with 30 ml of the same medium containing 0.4% agar. As positive control two seeds from a hygromycin-resistant line are sown at marked locations on each plate. Plates are cold-treated at 4°C for 2 days and subsequently subjected to alternating periods of 16 hours light at 21°C and 8 hours darkness at 16°C. Hygromycin resistance is evaluated each day for 8-15 days after sowing.

**Example 3: Molecular and Genetic Analysis of the Mutant**

Following identification of 11 hygromycin-resistant seedlings in one of the pools, the families forming this pool are re-screened individually. One family contains approximately 25% hygromycin-resistant seedlings. Six resistant plantlets of this family are transferred to larger vessels containing germination medium without hygromycin. After rosette formation and development of the root system, plants are transferred to soil for further growth and seed setting. Prior to potting, tissue explants are taken from each plant to generate callus cultures on RCA medium (Table 1) with or without 10 mg/l hygromycin B. Callus cultures are used as a source of material for DNA and RNA analyses and for a further confirmation of hygromycin resistance in this tissue.

Genomic DNA is isolated using a CTAB based method as described by Mittelsten Scheid et al, Mol Gen Genet 244: 325-330, 1994, and incubated with restriction enzymes *BamHI*, *HpaII*, *MspII*, *DraI*, *EcoRV*, *RcaI* or *HindIII*. Total RNA is obtained using a RNAeasy kit (Qiagen) according to the supplier's recommendation. Southern and northern blot analysis are performed under conditions described by Church and Gilbert, Proc Natl Acad Sci USA 81: 1991-1995, 1984, using DNA fragments labeled with <sup>32</sup>P by random prime labeling. The coding region of the *hpt* gene, or DNA consisting of the P35S promoter, *hpt* coding and terminator region, or the coding region of the *bar* gene together with the 1' promoter are used as probes.

Northern blot analysis of 4 hygromycin-resistant siblings shows restoration of transcription of the *hpt* gene. Southern blot analysis of said siblings indicates that there is no detectable rearrangement within the complex *hpt* insert. The *hpt* transgene complex in the mutant is still hypermethylated like in the original line A, as judged by Southern blot analysis with the methylation-sensitive restriction enzymes *HpaII* and *MspI*, and by genomic sequencing of the promoter region after treatment with bisulfate. There is also no influence of the mutation on the methylation of repetitive genomic DNA in contrast to that observed for the *som* mutations.

The hygromycin-resistant plants, as well as non-selected siblings from the same family are grown to set seeds, checked for Basta resistance in the next generation, and scored for the number and size of the T-DNA inserts by Southern analysis. The results demonstrate that the original T-DNA transformant must have contained 2 T-DNA insertions segregating

independently in the siblings. One insert co-segregates with the hygromycin resistant mutant phenotype. A plant homozygous for this insert and lacking the other T-DNA insert, is used for cloning the corresponding T-DNA insertion site.

Histochemical GUS staining of crosses between plants with mutant phenotype and the transgenic plant line GUS-TS (obtainable from Dr. H. Vaucheret, INRA, Versailles Cedex, France) of *Arabidopsis thaliana* ecotype Colombia containing a transcriptionally silenced locus with multiple copies of a chimeric beta-glucuronidase (*gus*) gene reveals reactivation of the silent GUS gene in the F2 progeny which are homozygous for the mom allele.

Inbreeding of plants with the *mom1* mutant phenotype does not result in any morphological abnormalities even in the 9th generation of inbreeding. This is in contrast to the *som* mutants.

Backcrossing of the mutant phenotype of *mom1* with line A (see example 1) results in immediate resiliencing of the reactivated *hpt* gene upon introduction of a wild-type **MOM** allele in F1 hybrids. This also is in contrast to the *som* mutants.

**Table 1: Composition of RCA medium**

<b>RCA medium</b>	
MS macro 10 x	100 ml
B5 micro 1000 x	1 ml
ferric citrate	5 ml
NT vitamins 100 x	10 ml
sucrose	10 g
MES	5 ml
agar	10 g
NAA	0.1 mg
BAP	1 mg
pH 5.8 (KOH)	
ad 1 l	

- 10 -

**MS macro 10 x**

potassium nitrate	19 g
ammonium nitrate	16.5 g
calcium chloride (x 2 H <sub>2</sub> O)	4.4 g
magnesium sulfate (x 7 H <sub>2</sub> O)	3.7 g
potassium dihydrogen phosphate	1.7 g
ad 1 l	

**B5 micro 1000 x**

magnesium sulfate (x H <sub>2</sub> O)	1000 mg
boric acid	300 mg
zinc sulfate (x 7 H <sub>2</sub> O)	200 mg
potassium iodide	75 mg
sodium molybdate (x 2 H <sub>2</sub> O)	25 mg
copper sulfate (x 5 H <sub>2</sub> O)	2.5 mg
cobalt chloride (x 6 H <sub>2</sub> O)	2.5 mg
ad 100 ml	

**ferrie citrate**

ammonium iron citrate	10 g
ad 1 l	

**NT vitamins 100 x**

myo-inositol	1000 mg
thiamine HCl	10 mg
ad 1 l	

**MES**

MES	14 g
pH 6 (NaOH)	
ad 100 ml	

**Example 4: Cloning of the "Silencing Gene"**

Genomic DNA from the plant containing only the T-DNA co-segregating with the hygromycin resistant mutant phenotype is isolated. The DNA is subjected to TAIL (thermal asymmetric interlaced) PCR according to Liu et al, Plant J 8: 457-463, 1995, using 3 specific, nested primers close to the right border of the T-DNA (5'-CAT CTA CGG CAA TGT ACC AGC-3' (SEQ ID NO: 4), 5'-GAT GGG AAT TGG CTG AGT GGC-3' (SEQ ID NO: 5), 5'-CAG TTC CAA ACG TAA AAC GGC-3' (SEQ ID NO: 6)) which are directed outwards, and one of several degenerate primers which might bind in flanking plant DNA. Two out of the following seven degenerate primers

AD1	5'-NTC GAS TWT SGW GTT-3' (Liu et al supra; SEQ ID NO: 7)
AD2	5'-NGT CGA SWG ANA WGA A-3' (Liu et al supra; SEQ ID NO: 8)
AD3	5'-WGT GNA GWA NCA NAG A-3' (Liu et al supra; SEQ ID NO: 9)
AD4	5'-WGG WAN CWG AWA NGC A-3' (SEQ ID NO: 10)
AD5	5'-WCG WWG AWC ANG NCG A-3' (SEQ ID NO: 11)
AD6	5'-WGC NAG TNA GWA NAA G-3' (SEQ ID NO: 12)
AD7	5'-AWG CAN GNC WGA NAT A-3' (SEQ ID NO: 13)

actually result in amplification of specific fragments. The larger one obtained using AD7 is cloned and sequenced. It contains 50 bp of the T-DNA and 275 bp of flanking plant DNA. In Southern blot analysis it is shown that this PCR fragment contains the plant DNA flanking the T-DNA. The PCR fragment is used to screen a genomic library (Stratagene) of wild type *Arabidopsis thaliana* ecotype Columbia. Three genomic clones hybridizing to the PCR fragment are identified. The genomic clones are further mapped with restriction enzymes, hybridized to the PCR fragment and aligned to each other. In one of the genomic clones obtained (p4A-11), the sequence found to flank the T-DNA of the insertion mutation is located approximately in the middle of the genomic sequence. An approximately 800 bp EcoRI-Sall fragment of p4A-11 is used to obtain the overlapping genomic clone p5-6, and an approximately 700 bp EcoRI fragment of p5-6 is used to obtain genomic clone p30-1 overlapping with p5-6. An approximately 700 bp HindIII fragment of p30-1 is used to obtain the genomic clone p33-19 overlapping with p30-1. Said clones are sequenced to design primers for RT-PCR. The approximately 700 bp EcoRI fragment of p5-6 is further used for screening of a cDNA library of wild type *Arabidopsis thaliana* ecotype Zurich according to



Elledge et al, Proc Natl Acad Sci USA 88: 1731-1735, 1991). Nine cDNA clones are obtained and the longest clone p17-8 having a length of 2.6 kb is sequenced.

#### Example 5: **Sequence Analysis and Alignments**

Taking into account the large size of the Arabidopsis silencing gene cloned above it cannot be entirely excluded that the authentic nucleotide and amino acid sequences of the gene and protein, respectively, might deviate from the sequences given in SEQ ID NO: 1, SEQ ID NO: 2, and SEQ ID NO: 3 at a few positions due to mutations arising from the cloning procedure or due to ambiguities in the sequencing reactions. Additionally, sequencing of DNA derived from a different ecotype can reveal allelic differences. Thus, the sequences of SEQ ID NO: 1, SEQ ID NO: 2, and SEQ ID NO: 3 represent the corresponding genes and proteins of *Arabidopsis thaliana* ecotype Zurich, whereas genomic sequences obtained from *Arabidopsis thaliana* ecotype Columbia reveal two mismatches at nucleotide positions 4338 (A instead of T) and 6721 (T instead of G) of SEQ ID NO: 1, which result in an amino acid residue K instead of M at position 705 of SEQ ID NO: 3 and an amino acid residue D instead of E at position 1219 of SEQ ID NO: 3.

The 2.6 kb cDNA clone is analyzed sequentially from both ends and is shown to contain one large ORF as well as a 3' untranslated sequence.

Analysis of the genomic clones reveals that clones p4A-11 and p5-6 contain sequences homologous to the cDNA sequence as well as 7 intron sequences. Comparing the genomic sequences with the DNA sequences flanking the T-DNA insert, it turns out that the T-DNA insertion causes a deletion of about 2 kb of genomic DNA. The 5' end of the deletion is located in an intron (intron 12) and the 3' end of the deletion is located downstream of the 3' end of the cDNA. The sequence of 5' end of the cDNA clone terminates in the middle of the sequence of the genomic clone p5-6. Three independent nested RT-PCR reactions are performed to obtain additional cDNA sequences further upstream. The sequences of the primers used for these RT-PCRs are as follows:

RT1-1	5' -CTGTACATACTGAGTACAATCGGA-3'	(SEQ ID NO: 14)
RT1-2	5' -GCTTCAATTCTGCCTCAGTTGAAC-3'	(SEQ ID NO: 15)
RT1-3	5' -CTCTACGTGCTTAACATCATGCGA-3'	(SEQ ID NO: 16)
RT1-4	5' -CCAGCTTCTGCTACTAGAAAGTCAG-3'	(SEQ ID NO: 17)

RT2/3-1	5' -CTGGAGTTGCATGAAATCCTGGATG-3'	(SEQ ID NO: 18)
RT2/3-2	5' -GCTCTTTGTAAGCTGTTTCACGAGAC-3'	(SEQ ID NO: 19)
RT2-3	5' -TCGCATGATGTTAAGCACGTAGAG-3'	(SEQ ID NO: 20)
RT2-4	5' -GAGTACTGGTCCGTGAACAGGTAAT-3'	(SEQ ID NO: 21)
RT3-3	5' -ATGCTTGACACAAGCATGGTCGGAAA-3'	(SEQ ID NO: 22)
RT3-4	5' -TGCAACATCGTGCATTTGCTCCAGA-3'	(SEQ ID NO: 23)
RT4-1	5' -CACAAGCATGAGTTTTTTCCTTCCGG-3'	(SEQ ID NO: 24)
RT4-2	5' -CTGACTTTCTAGTAGCAGAAGCTGG-3'	(SEQ ID NO: 25)

Sequences of several parts of the genomic clones are found to be deposited in the *Arabidopsis* database (accession numbers B67281, B62563, B20434, B20425, B21274, B08967, B11993, B20116, B12496 and B10852 as end sequences of BAC, and Z18494 and AA597930 as partial cDNA sequences, on 13 Apr 1999). A comparison of the encoded protein sequence with the Swiss Protein Database reveals partial similarity with ATPase/helicase proteins of the SWI2/SNF2 family (amino acid position 479 to 719 in SEQ ID NO: 3). The encoded protein consists of 2001 amino acids and is calculated to have a molecular weight of 219 kD and a pI of 5.1. An ATP/GTP-binding motif (amino acid position 460 to 467 in SEQ ID NO: 3) and three nuclear localization motifs (amino acid positions 362 to 367, 832 to 838 and 858 to 862 in SEQ ID NO: 3) are found in the encoded protein. Subcellular immunodetection of HA-tagged MOM protein confirms its nuclear localization. Similarity to the actin binding domain of chicken tensin (amino acid position 1899 to 1941 in SEQ ID NO: 3) and a predicted membrane spanning domain (amino acid position 995 to 1015 in SEQ ID NO: 3) are also detected. Additionally, the encoded protein contains three types of repetitive regions or internal repeats essentially defined by amino acid positions 177 to 350, 1462 to 1672 and 1848 to 1894 OF SEQ ID NO: 3.

#### Example 6: *Homologous genes in other species*

A putative proline/hydroxyproline-rich glycoprotein of *Arabidopsis thaliana* showing partial similarity to the MOM protein is disclosed as GenBank accession number AAD29829). The similarity is 34-47% depending on the region and is only seen in the second half of the MOM protein (i.e. amino acids 1368 to 1944).

The MOM cDNA clone is used to probe genomic DNA from turnip, tomato, tobacco, maize, mouse, fruit fly and man for the presence of homologous genes by Southern blot analysis. Hybridization under conditions of low stringency is found in all cases. Cross-hybridizing clones from libraries can be identified and sequenced.

A genomic library of the *Brassica oleracea* var. *acephala* (obtained from Dr. Mark Cock, INRA, CNRS, Lyon, France) are screened with the *MOM* cDNA under stringent conditions. Two positive clones are obtained, subcloned, and partially sequenced. Partial sequences of clone 1 show similarity to different regions in the *MOM* gene (80-86% at DNA level and 62-80% at amino acid level) which encode the N-terminal, ATPase, and C-terminal parts of the MOM protein. All three putative nuclear localization sequences of the MOM protein are fully conserved in clone 1. Partial sequences of clone 2 also show similarity regions in the *MOM* gene (64-76% at DNA level and 55-64% at amino acid level) which encode the ATPase, putative transmembrane, and C-terminal parts of the MOM protein. The sequences of clones 1 and 2 are not identical, suggesting the presence of, at least, two homologous genes in *Brassica oleracea*. Examples of partial sequences obtained from clone 1 and 2 are given in SEQ ID Nos: 26-33.

Additionally a genomic library of *Brassica rapa* (obtained from Dr. Kinuya Toriyama, Tohoku University, Sendai, Japan) is screened with the *MOM* cDNA under stringent conditions. Positive signals hybridizing to both a 5' and a 3' part of the *MOM* cDNA are obtained.

Furthermore, a genomic library of *Petunia hybrida* (obtained from Dr. Jan Kooter, Vrije Universiteit, Amsterdam, The Netherlands) is screened with *MOM* cDNA under less stringent conditions. Positive signals hybridizing to both the 5' and 3' part of the *MOM* cDNA are obtained.

**Example 7: *Manipulating marker gene expression by antisense constructs***

The 2.6 kb cDNA fragment and a 1.8 kb RT-PCR fragment amplified by a nested RT-PCR using primers RT1-1 and RT1-2 for the first PCR and primers RT1-3 and RT1-4 for the second PCR, are each inversely cloned into the multiple cloning site of the binary vector pbarbi53 to generate antisense RNA. pbarbi53 is a modified vector of p1'barbi and carries

- 15 -

an expression cassette consisting of the 35S promoter of cauliflower mosaic virus, a multiple cloning site containing Xho I, SnaBI, Hpa I and Cla I restriction sites and the 35S terminator of cauliflower mosaic virus at the HindIII site of p1'barbi. The resulting recombinant plasmids are introduced into *Agrobacterium* as described in Example 1. The transgenic plant line GUS-TS (obtainable from Dr. H. Vaucheret, INRA, Versailles Cedex, France) of *Arabidopsis thaliana* ecotype Colombia containing a transcriptionally silenced locus with multiple copies of a chimeric beta-glucuronidase (*gus*) gene, is transformed with the recombinant plasmids as described in Example 1 and transformants are selected as described by Mengiste et al, Plant J 12: 945-948, 1997. pbarbi53 vector DNA is used in control transformations. The transformants are examined for reactivation of the *gus* gene by histochemical staining. A cotyledon leaf is soaked in *gus* staining solution (100 mM sodium phosphate buffer (pH 7.0), 0.05% 5-bromo-4-chloro-3-indolyl-beta-D-glucuronidase, 0.1% sodium azide) under vacuum for 10 min and then incubated at 37°C overnight. While strong *gus* activity is observed in the plants transformed with the recombinant plasmid carrying the 2.6 kb cDNA, plants transformed with the recombinant plasmid carrying the 1.8 kb RT-PCR fragment or pbarbi53 do not show any *gus* activity above background. Therefore, expression of the antisense RNA of the 2.6 kb cDNA mimicks the mutant phenotype and confirms that sequences shown in SEQ ID NO: 1, SEQ ID NO: 2 and SEQ ID NO: 3 represent the genetic information for a component of the transcriptional gene silencing system.

- 16 -

**What is claimed is:**

1. DNA comprising an open reading frame encoding a protein characterized by an amino acid sequence comprising a component sequence of at least 150 amino acid residues having 40% or more identity with an aligned component sequence of SEQ ID NO: 3.
2. The DNA according to claim 1 comprising an open reading frame encoding a protein having the formula  $R_1-R_2-R_3$ , wherein
  - $R_1$ ,  $R_2$  and  $R_3$  constitute component sequences consisting of amino acid residues independently selected from the group of the amino acid residues Gly, Ala, Val, Leu, Ile, Phe, Pro, Ser, Thr, Cys, Met, Trp, Tyr, Asn, Gln, Asp, Glu, Lys, Arg, and His,
  - $R_1$  and  $R_3$  consist independently of 0 to 3000 amino acid residues;
  - $R_2$  consists of at least 150 amino acid residues; and
  - $R_2$  is at least 40% identical to an aligned component sequence of SEQ ID NO: 3.
3. The DNA according to claim 1 comprising an open reading frame encoding one or more SWI2/SNF2-like ATPase/hellcase motifs.
4. The DNA according to claim 1 comprising an open reading frame encoding a protein having a component sequence defined by amino acids 478-490, 584-600, 617-630, 654-668, 676-690, 718-734, 776-788, 1222-1233, 1738-1749 or 1761-1770 of SEQ ID NO: 3.
5. The DNA according to claim 1, wherein the open reading frame encodes a protein characterized by the amino acid sequence of SEQ ID NO: 3, an allelic amino acid sequence having amino acid residue K instead of M at position 705 of SEQ ID NO: 3, or an amino acid residue D instead of E at position 1219 of SEQ ID NO: 3.
6. The DNA according to claim 1 characterized by the nucleotide sequence of SEQ ID NO: 1 or SEQ ID NO: 2.
7. The DNA according to claim 1, ~~wherein expression of RNA, complementary to mRNA transcribed therefrom, characterized in that expression of corresponding anti-sense RNA in a cell releases silencing of a transgenic marker gene.~~
8. The protein encoded by the open reading frame of any one of claims 1 to 7.

AMENDED SHEET

- 17 -

9. A method of producing DNA according to claim 1, comprising
  - screening a DNA library for clones which are capable of hybridizing to a fragment of the DNA defined by SEQ ID NO: 1 or SEQ ID NO: 2, wherein said fragment has a length of at least 15 nucleotides;
  - sequencing hybridizing clones;
  - purifying vector DNA of clones comprising an open reading frame encoding a protein characterized by an amino acid sequence comprising a component sequence of at least 150 amino acid residues having 40% or more sequence identity to SEQ ID NO: 3
  - optionally further processing the purified DNA.
10. A polymerase chain reaction wherein at least one oligonucleotide used comprises a sequence of nucleotides which represents 15 or more basepairs of SEQ ID NO: 1 or SEQ ID NO: 2.

## (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau(43) International Publication Date  
4 January 2001 (04.01.2001) ✓

PCT

(10) International Publication Number  
**WO 01/00801/A2**(51) International Patent Classification<sup>7</sup>: C12N 15/00

(CH). PASZKOWSKI, Jerzy [PL/CH]; Blauenweg 10, CH-4224 Nenzlingen (CH).

(21) International Application Number: PCT/EP00/05761

(74) Agent: **BECKER, Konrad**; Novartis AG, Patent and Trademark Dept., Agribusiness, Site Rosental, CH-4002 Basel (CH).

(22) International Filing Date: 21 June 2000 (21.06.2000)

(25) Filing Language: English

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(26) Publication Language: English

(30) Priority Data:  
9914623.5 23 June 1999 (23.06.1999) GB(71) Applicant (*for all designated States except AT, US*): **NOVARTIS AG** [CH/CH]; Schwarzwaldallee 215, CH-4058 Basel (CH).(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).(71) Applicant (*for AT only*): **NOVARTIS-ERFINDUNGEN VERWALTUNGSGESELLSCHAFT M.B.H.** [AT/AT]; Brunner Strasse 59, A-1230 Vienna (AT).**Published:**

— Without international search report and to be republished upon receipt of that report

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **HABU, Yoshiki** [JP/CH]; Im Niederholzboden 54, CH-4125 Riehen (CH). **MITTELSTEN SCHEID, Ortrun** [DE/CH]; Martinskirchplatz 15, CH-4051 Basel (CH). **AMEDEO, Paolo** [IT/CH]; Eimeldingerweg 45, CH-4057 Basel

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: GENE INVOLVED IN EPIGENETIC GENE SILENCING

(57) Abstract: The present invention relates to DNA which encodes proteins involved in gene silencing. Related genes encoding proteins characterized by an amino acid sequence comprising a component sequence of at least 150 amino acid residues having 40% or more identity with an aligned component sequence of SEQ ID NO:3 can be isolated from different sources such as mammalian or plant cells. Further disclosed is a method for isolating DNA according to the invention.

WO 01/00801 A2

**DECLARATION AND POWER OF ATTORNEY FOR UNITED STATES PATENT APPLICATION**☒ Original☐ Supplemental☐ Substitute

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name, and

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if more than one name is listed below) of the subject matter which is claimed and for which a United States patent is sought on the invention entitled

**GENE INVOLVED IN EPIGENETIC GENE SILENCING**

the specification of which:

☐ is attached hereto.

☐ was filed on \_\_\_\_\_ as Application No. \_\_\_\_\_  
(day/month/year)

and, if this box (☐) contains an \*

☐ was amended on \_\_\_\_\_  
(day/month/year)

☒ was filed as Patent Cooperation Treaty international Application No.

PCT/EP00/05761 on 21.06.00  
(day/month/year)

and, if this box (☐) contains an \*

☐ entered the national stage in the United States and was accorded Application No. \_\_\_\_\_

and, if this box (☐) contains an \*

☐ was amended, subsequent to entry into the national stage, on \_\_\_\_\_  
(day/month/year)

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment(s) referred to above and, if this application was filed as a Patent Cooperation Treaty international application, by any amendments made during the international stage (including any made under Patent Cooperation Treaty Rule 91, Article 19 and Article 34).

I acknowledge my duty to disclose all information which is known by me to be material to the patentability of this application as defined in 37 C.F.R. § 1.56.



I hereby claim the benefit under 35 U.S.C. §119(a)-(d) or §365(b) of any foreign application(s) for patent or inventor's certificate listed below and under 35 U.S.C. §365(a) of any Patent Cooperation Treaty international application(s) designating at least one country other than the United States listed below and have also listed below any foreign application(s) for patent or inventor's certificate and Patent Cooperation Treaty international application(s) designating at least one country other than the United States for the same subject matter and having a filing date before that of the application the priority of which is claimed for that subject matter:

COUNTRY/REGION (OR P.C.T.)	APPLICATION No.	FILING DATE (day/month/year)	PRIORITY CLAIMED	
GB	9914623.5	23.06.99	<input checked="" type="checkbox"/> Yes	<input type="checkbox"/> No
			<input type="checkbox"/> Yes	<input type="checkbox"/> No
			<input type="checkbox"/> Yes	<input type="checkbox"/> No
			<input type="checkbox"/> Yes	<input type="checkbox"/> No
			<input type="checkbox"/> Yes	<input type="checkbox"/> No

I hereby claim the benefit under 35 U.S.C. § 119 (e) of any United States provisional application(s) listed below:

APPLICATION NO.	FILING DATE (day/month/year)
-----------------	---------------------------------

I hereby claim the benefit under 35 U.S.C. §120 of any United States application(s) listed below and under 35 U.S.C. §365(c) of any Patent Cooperation Treaty international application(s) designating the United States listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in said prior application(s) in the manner required by the first paragraph of 35 U.S.C. §112, I acknowledge my duty to disclose all information known to me to be material to patentability as defined in 37 C.F.R. §1.56 which became available between the filing date(s) of the prior application(s) and the national or Patent Cooperation Treaty international filing date of this application:

United States Application No.	United States Filing Date (day/month/year)	Status (Pending, Abandoned or U.S. Patent No.)	International Application No. and Filing Date (day/month/year)
----------------------------------	--	--	--

US Case S -31005A

I hereby appoint the registered practitioners associated with Customer No. 022847, respectively and individually, as my attorneys and agents, with full power of substitution and revocation, to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith.

If these brackets contain an X [X], I hereby authorize the registered practitioners associated with Customer No. 022847 and any others acting on my behalf to take any action relating to this application based on communications from the Patents and Trademarks Division of Syngenta Crop Protection AG, Basle, Switzerland, or an affiliate thereof or a successor thereto, without direct communication from me.

Please address all communications to the address associated with Customer No. 022847, which is currently Larry W. Stults, Syngenta, Patent and Trademark Department, 3054 Cornwallis Road, Research Triangle Park, NC 27709.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under 18 U.S.C. §1001 and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Full name of sole  
or first joint inventor

Yoshiki HABU

Inventor's signature

Yoshiki Habu

Date

20.11.2001  
(day/month/year)

Residence

4125 Riehen, Switzerland CHX

Citizenship

Japanese

Post Office Address

Gstaltenrainweg 71  
4125 Riehen  
CH

**IMPORTANT:** Before this declaration is signed, the patent application (the specification, the claims and this declaration) must be read and understood by each person signing it, and no changes may be made in the application after this declaration has been signed.

US Case S -31005A

2-0  
Full name of second  
joint inventor, if anyOrtrun MITTELSTEN SCHEID

Inventor's signature

Ortrun Mittelsten Scheid

Date

20.11.2001

(day/month/year)

Residence

4051 Basel, Switzerland CHX

Citizenship

German

Post Office Address

Martinskirchplatz 15  
4051 Basel  
CHFull name of third  
joint inventor, if anyPaolo AMEDEO3-0  
Inventor's signature

Date

(day/month/year)

Residence

San Diego, CA 92121-1125, USA

Citizenship

Italian

Post Office Address

Torrey Mesa Research Institute Inc.  
3115 Merryfield Row  
San Diego, CA 92121-1125  
USA4-0  
Full name of fourth  
joint inventor, if anyJerzy PASZKOWSKI

Inventor's signature

Jerzy Paszkowski

Date

20.11.2001

(day/month/year)

Residence

4224 Nenzlingen, Switzerland CHX

Citizenship

Polish

Post Office Address

Blauenweg 10  
4224 Nenzlingen  
CH

**DECLARATION AND POWER OF ATTORNEY FOR UNITED STATES PATENT APPLICATION**☒ Original☐ Supplemental☐ Substitute

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name, and

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if more than one name is listed below) of the subject matter which is claimed and for which a United States patent is sought on the invention entitled

**GENE INVOLVED IN EPIGENETIC GENE SILENCING**

the specification of which:

☐ is attached hereto.

☐ was filed on \_\_\_\_\_ as Application No. \_\_\_\_\_  
(day/month/year)

and, if this box (☐) contains an \*

☐ was amended on \_\_\_\_\_  
(day/month/year)

☒ was filed as Patent Cooperation Treaty international Application No. .

PCT/EP00/05761 on 21.06.00  
(day/month/year)

and, if this box (☐) contains an \*

☐ entered the national stage in the United States and was accorded Application No. \_\_\_\_\_

and, if this box (☐) contains an \*

☐ was amended, subsequent to entry into the national stage, on \_\_\_\_\_  
(day/month/year)

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment(s) referred to above and, if this application was filed as a Patent Cooperation Treaty international application, by any amendments made during the international stage (including any made under Patent Cooperation Treaty Rule 91, Article 19 and Article 34).

I acknowledge my duty to disclose all information which is known by me to be material to the patentability of this application as defined in 37 C.F.R. § 1.56.

US Case S -31005A

I hereby claim the benefit under 35 U.S.C. §119(a)-(d) or §365(b) of any foreign application(s) for patent or inventor's certificate listed below and under 35 U.S.C. §365(a) of any Patent Cooperation Treaty international application(s) designating at least one country other than the United States listed below and have also listed below any foreign application(s) for patent or inventor's certificate and Patent Cooperation Treaty international application(s) designating at least one country other than the United States for the same subject matter and having a filing date before that of the application the priority of which is claimed for that subject matter:

COUNTRY/REGION (OR P.C.T.)	APPLICATION No.	FILING DATE (day/month/year)	PRIORITY CLAIMED	
GB	9914623.5	23.06.99	<input checked="" type="checkbox"/> Yes	<input type="checkbox"/> No
			<input type="checkbox"/> Yes	<input type="checkbox"/> No
			<input type="checkbox"/> Yes	<input type="checkbox"/> No
			<input type="checkbox"/> Yes	<input type="checkbox"/> No
			<input type="checkbox"/> Yes	<input type="checkbox"/> No

I hereby claim the benefit under 35 U.S.C. § 119 (e) of any United States provisional application(s) listed below:

APPLICATION NO.	FILING DATE (day/month/year)
-----------------	---------------------------------

I hereby claim the benefit under 35 U.S.C. §120 of any United States application(s) listed below and under 35 U.S.C. §365(c) of any Patent Cooperation Treaty international application(s) designating the United States listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in said prior application(s) in the manner required by the first paragraph of 35 U.S.C. §112, I acknowledge my duty to disclose all information known to me to be material to patentability as defined in 37 C.F.R. §1.56 which became available between the filing date(s) of the prior application(s) and the national or Patent Cooperation Treaty international filing date of this application:

United States Application No.	United States Filing Date (day/month/year)	Status (Pending, Abandoned or U.S. Patent No.)	International Application No. and Filing Date (day/month/year)
----------------------------------	--	--	--

US Case S -31005A

I hereby appoint the registered practitioners associated with Customer No. 022847, respectively and individually, as my attorneys and agents, with full power of substitution and revocation, to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith.

If these brackets contain an X [X], I hereby authorize the registered practitioners associated with Customer No. 022847 and any others acting on my behalf to take any action relating to this application based on communications from the Patents and Trademarks Division of Syngenta Crop Protection AG, Basle, Switzerland, or an affiliate thereof or a successor thereto, without direct communication from me.

Please address all communications to the address associated with Customer No. 022847, which is currently Larry W. Stults, Syngenta, Patent and Trademark Department, 3054 Cornwallis Road, Research Triangle Park, NC 27709.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under 18 U.S.C. §1001 and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Full name of sole  
or first joint inventor

**Yoshiki HABU**

Inventor's signature

Date

(day/month/year)

Residence

**4125 Riehen, Switzerland**

Citizenship

**Japanese**

Post Office Address

**Gstaltenrainweg 71  
4125 Riehen  
CH**

**IMPORTANT:** Before this declaration is signed, the patent application (the specification, the claims and this declaration) must be read and understood by each person signing it, and no changes may be made in the application after this declaration has been signed.

US Case S -31005A

Full name of second  
joint inventor, if any

**Ortrun MITTELSTEN SCHEID**

Inventor's signature

Date

(day/month/year)

Residence

**4051 Basel, Switzerland**

Citizenship

**German**

Post Office Address

**Martinskirchplatz 15  
4051 Basel  
CH**

Full name of third  
joint inventor, if any

**Paolo AMEDEO**

Inventor's signature



Date

05/12/2001  
(day/month/year)

Residence

**San Diego, CA 92121-1125, USA**

Citizenship

**Italian**

Post Office Address

**Torrey Mesa Research Institute Inc.  
3115 Merryfield Row  
San Diego, CA 92121-1125  
USA**

Full name of fourth  
joint inventor, if any

**Jerzy PASZKOWSKI**

Inventor's signature

Date

(day/month/year)

Residence

**4224 Nenzlingen, Switzerland**

Citizenship

**Polish**

Post Office Address

**Blauenweg 10  
4224 Nenzlingen  
CH**

```

<110> Novartis AG
      Novartis Research Foundation
<120> Gene involved in epigenetic gene silencing
<130> S-31005A
<140>
<141>
<150> GB 9914623.5
<151> 1999-06-23
<160> 33
<170> PatentIn Ver. 2.1
<210> 1
<211> 10329
<212> DNA
<213> Arabidopsis thaliana
<220>
<221> intron
<222> (1009)..(1295)
<220>
<221> intron
<222> (2551)..(2673)
<220>
<221> intron
<222> (2753)..(2867)
<220>
<221> intron
<222> (3114)..(3506)
<220>
<221> intron
<222> (3681)..(3973)
<220>
<221> intron
<222> (4896)..(4975)
<220>
<221> intron
<222> (5218)..(5777)
<220>
<221> intron

```



WO 01/00801

PCT/EP00/05761

- 2 -

<222> (5883) .. (6082)

<220>

<221> intron

<222> (7481) .. (7615)

<220>

<221> intron

<222> (7772) .. (7914)

<220>

<221> intron

<222> (8071) .. (8153)

<220>

<221> intron

<222> (8319) .. (8451)

<220>

<221> intron

<222> (8630) .. (8718)

<220>

<221> intron

<222> (8919) .. (9000)

<220>

<221> intron

<222> (9212) .. (9284)

<400> 1

aatattttaag	tttggtttat	attctttcta	gtaatctttg	aaatattgta	agagataatg	60
cttctaataa	ataacattgg	atttattgga	attaatgtat	tgaaaaaact	atgcaaatac	120
tacagtgtat	tttggaaacga	ccaaaatgat	atatgtaaac	tttcgttcta	gtcttctaca	180
tagtgtaata	ggatagcggg	caaggttgat	cgactctaaa	cattatgggt	acgtaattcc	240
gcagtgggta	cagtctactg	tcgaggccaa	actggtaatt	aaacgtttga	agtttagaga	300
aatatttttga	tgatgagtac	cacaatcaaa	gatgataggt	gttaatcact	gtaaaaatgt	360
tgattgaata	ctacgaatgc	agaacatata	catattttta	atctctttgg	aatttttggt	420
tttgttttta	tcatttttga	atacacgaag	agctcagtta	tatttcatat	tgtatatgaa	480
tttgttctat	ttaatcttca	attctagcaa	catactctta	tgctaattcg	tttcataatt	540
tagtatagta	taaaaaattac	aaatttcaaa	acaaactata	agtaatatatac	taacatagtc	600
ggtgtaacat	ttcgtttaatt	tcacataaca	tatgttaatt	acatatgtac	actatttttg	660
aagtatttta	taacttaaaa	tatataaaatt	taaatctaag	aaatcacaag	catgagtttt	720
tccttccggg	aatcgtaaaa	tcaaaaatcg	ctcgctcgag	aaacgccggg	gctagaagag	780
gaaagtaccg	tacataatcc	tgcgaaacca	attctcgtct	tcttcaaact	cagttttccg	840
aaaccccaaa	caccgcgagg	attgcatggc	ctgaagaacc	acttaatcga	gaattgtgct	900
ggaattctca	aattttccct	cgcgtttttc	tttcacactc	tcggaatcgg	aaattttccac	960
caagctcogt	caagcgatag	attctgacaa	ttacacactt	tcgcgcaggt	atgcttcctt	1020
ccctgtttta	ggttggtggt	aatctatcgg	tgaatcgaag	gttttggggc	tcgggctttg	1080
cgttttaggt	ttttcagaga	atcttatcta	cttggggatg	gatcttaggc	gtttgttaga	1140
tgtaactcat	tagttttgca	tataggaatt	ttgatttgaa	agttaggtcg	ccggattttg	1200
agacattttg	tttgatggtc	ttcttcgggtg	ctcacattct	ttgtttttta	gtgcttgatt	1260
tggttgctaa	ggctccttcc	gttgcggtgct	ctcagtgaat	atgaagaaag	atgaaaagat	1320
tggtttgacg	gggagaacca	tttacaccag	atccctagca	gcttcaattc	ctgcctcagt	1380
tgaacaagaa	acccttggtt	tgaggagggtc	aagccggggg	acaccatcta	cgaaggtaat	1440

aactccagct	tctgctacta	gaaagtcaga	gagactgggt	ccctcacctg	cttcagtttc	1500
aaaaaagtc	ggtggaatcg	tcaagaattc	cacaccaagt	tctttgcgaa	ggtccaatag	1560
ggggaagact	gaagtatcct	tgcagagttc	caaaggatca	gataattcta	tcaggaaagg	1620
agatacttca	ccggatattg	agcagagaaa	ggatagtgtt	gaagagtcga	cagataagat	1680
caagcctata	atgtcagccc	gaagttacag	ggcattgttt	agagggaagc	tcaaggaatc	1740
tgaggcatta	gttgatgctt	ccccaaatga	agaggaacta	gtagtgtgtg	gttggttctcg	1800
ccgcatacct	gcaggcaatg	atgatgttca	aggtaaaaca	gattgtccac	cacctgcaga	1860
tgcaggatca	aaaaggctgc	cagttgacga	aactagtttg	gacaagggca	ctgattttcc	1920
tttgaaatca	gttacggaga	ccgagaagat	agtgttgat	gcacccccca	tagttgaaac	1980
tggggatgac	agtgttatag	gttcaccatc	tgagaattta	gagacacaaa	agcttcaaga	2040
tggttaagaca	gattgtttcac	cacctgcaaa	tgcagaatcg	aaaacgctgc	cagttgggtga	2100
aactagttta	gaaaaagaat	atccacaaaa	gtttcaagat	gataacacag	attgtctacc	2160
acctgcaaat	gcagaatcaa	aaaggctgcc	agttggcgaa	actagtttag	aaaaggacac	2220
tgattttcct	ttgaaatcaa	ctacggagac	tggaaagatg	gttctttatg	catcccccat	2280
agttgaaact	agggatgaca	gcgttatatg	ttcaccatct	acaaatttag	aaacccaaaa	2340
gcttcttgct	agtaaaactg	gcttagaaac	cgacatagtt	ttgcctttga	aaagaaaaag	2400
agacactgca	gaaattgagc	tggatgcatg	tgctacagtt	gcaaatggag	atgatcacgt	2460
tatgagttct	gatggggcca	ttccatctcc	atctgggtgc	aaaaatgata	atcgacctga	2520
aatgtgcaac	acgtgtaaaa	aacggcaaaa	gtaagagttt	ttttagtgtt	gtctgtctat	2580
tgaaacgatc	tgccaatggt	gaatgttggg	cagatgggtt	tgattcttag	gatatatgtt	2640
ctgtattgta	atgagttggt	caaaattttg	aagggtcaac	ggtgattgtc	aaaataggag	2700
tgtttgctcc	tgcattgtcc	agccagttga	agaatctgat	aacgtgacac	aggttgggtt	2760
ctaattactt	tccggagacc	gttaatcagt	ggactcttaa	atagtttagat	actagattta	2820
cttatccttt	tacttgtaat	ctgcaattct	attttgcatt	tgattaggat	atgaaagaaa	2880
ctggaccagt	tacgagcaga	gaatatgagg	agaacgggca	aatacaacat	ggtaaatcaa	2940
gtgatcccaa	attctattct	tccgtgtacc	cagagtattg	ggttcctgtg	cagctatcac	3000
atgtacagct	ggagcaatcc	tgtcagactc	tcttctccaa	atccttatct	ctttcttcac	3060
tttcgaagat	tgatcttggg	gctctagaag	aaactctcaa	ttctgtaaga	aaagtaagtt	3120
acttgatttt	aaaaacactt	attcttcaat	gcacttgtga	gttaagtacc	cagttattac	3180
tgggtgataag	ataaagaaag	caatagaaaa	attgataagg	tgttcacccg	attgcagcca	3240
aaaaaacaat	tctgtgttcc	atgctttcaa	gaggttgcga	cataggtgtt	atgcctttct	3300
gtttgatgtt	tggtagagca	aaggttttgg	gtctatttgt	tttatgcttt	tttgaaacac	3360
atagaacctg	gcaaacttga	cagttttggg	gttgcttaga	tatacgacta	ttgtcgggtca	3420
gcacacattt	ttctcaaggc	ctctttctgc	atgttaatgt	gtgaatatat	taaaatcttc	3480
tttatgtgtt	tgcaacttgt	tgacagacct	gtgaccatcc	atacgttatg	gatgcattct	3540
tgaacaactc	gctcaccaag	aatctggagt	tgcatgaaat	cctggatgta	gaaattaaag	3600
cgagcgggaa	acttcacctc	cttgataaaa	tgcttactca	tataaaaaag	aatgggttaa	3660
aagcagttgt	cttctaccag	gtgcattttc	tattacttgc	gaatgtgaat	agctctatgt	3720
ttgtcatgaa	tacgtcactt	tgtgcattct	caatatatgt	gcattttctt	tttgacaatg	3780
gaattctgtc	ttgtattgaa	atttgagtgg	gatgaaagta	tgctttttat	cgtgcaatta	3840
tgaagtgtaa	gttagccttc	agcagtcagc	tagcattatg	agatatgctg	aactaaaatg	3900
tttcttttct	cttcttttct	tttcgttata	tgtgcctcat	gtatgtttga	attacagttt	3960
ttatttttcag	caggcaacac	aaacccctga	agggcttctg	cttggttaata	ttctcgaaga	4020
ttttgtgggt	caaagatttg	gtccaaaatc	ttatgagcat	gggatataat	cctcaaagaa	4080
gaactccgct	ataaacaatt	tcaacaagga	gagtcgaatc	tggtgtctgc	tggtggaaac	4140
acgtgcctgc	agtcaaaacca	ttaaactctt	gcgagctgat	gcgtttatct	tttttgggaag	4200
cagcttgaat	ccatcgcatg	atgttaagca	cgtagagaag	ataaaaaatc	agtcattgtt	4260
tgaagaactc	aagatattcc	gattgtactc	agtatgtaca	gttgaagaaa	aagccctgat	4320
tctggctagg	caaaatatgc	ggcaaaaata	agctgtagag	aacctaaacc	gctctctcac	4380
gcacgcactg	ctcatgtggg	gggcgtcata	cttatttgat	aaactggatc	attttcacag	4440
cagtgaactc	ccagattcag	gagtttcatt	tgaacaatct	attatggacg	gcgtgattca	4500
tgaattctcg	tccatacttt	cttccaaagg	tggagaagaa	aatgaagtca	agctgtgtct	4560
acttttggag	ccaagcatg	ctcaggggac	ttcacagcag	gattctactc	tatttgggtga	4620
agaccatatt	aagttgtcag	atgaagagag	tccaatatata	ttttggtcaa	agctgttggg	4680
gggaaaaaat	cctatgtgga	aatacccttc	agatactccc	caaaggaatc	gaaaacgagt	4740

WO 01/00801

PCT/EP00/05761

- 4 -

tcagtatttt	gaggggttctg	aagcgaggtcc	caaaactggc	gatgggtggaa	atgcaaagaa	4800
gcgaaagaag	gcttctgatg	atgtcactga	tccccgggtc	actgatccgc	cagtagatga	4860
tgatgaaaga	aaggcctctg	ggaaggatca	catgggtaaa	atagtttaat	ttctgctccg	4920
atacctctag	tggtcattga	ttatgcaact	actttgctga	ctatctttcc	tacagggggt	4980
ttggagtcac	caaaagtcac	aacactccag	tcacatgtga	aatcttctgg	tacagatggg	5040
acattggatg	gaaatgatgc	ttttggcttg	tattctatgg	gcagccatat	ctctggaatc	5100
ccagaggata	tgtagctag	tcaagattgg	gggaaaatac	cggatgaatc	acagaggagg	5160
ctccacactg	ttttaagcc	gaagatggca	aaactttgcc	aagttttgca	tctttcagta	5220
agtggccttt	ttcacctcca	caacttattt	tagccttgca	tatgcttata	tatagctgat	5280
tgcaactgta	gttgttacct	gatttcctgt	tacagccaaa	tgtgagagtt	ttattcttca	5340
actatatcca	tccgtttaag	catattttat	ttcttatatc	tggcttcgtt	accaatgcac	5400
tgtaaaatg	agcaactgct	gcacaaaaca	gtaggtagtt	atgtgcctca	tgctattcat	5460
tgtttattga	agcaaagaaa	tttctgtcta	ctttacatga	tccatctgtg	ggagtatata	5520
actatatata	accttaggcc	tttgtacctg	gctgatcaaa	gacatgtcaa	aagtttatct	5580
gttcgctgtt	ggtatagaaa	ctaatacagt	gtctgatget	attttaaggt	agtcttatgt	5640
cttcacatat	tggtctaatg	atgtttccgc	tgctgtgtcc	atatacttct	gtgattatca	5700
cgggtgctccg	tctatcaaaa	ttgtactaaa	aggtattttg	caatgtgtga	ttggtaaca	5760
gattattttg	ttttcaggat	gcttgcacaa	gcatgggtcg	aaattttctc	gaatatgtta	5820
ttgaaaatca	ccgaatctac	gaagagccag	ccactacttt	tcaggcattc	cagatagccc	5880
tggtatgaca	gcatttactt	tgataattta	tgcatgtgtt	ccttcacatc	ctgcctttgt	5940
ttagaatgtc	ctcagaaggc	agcactcctt	tagttttaac	tttccaatca	taggattcaa	6000
atatccattt	actggccttt	gatcgctgca	taatatatga	atagttgaca	tactgaatac	6060
gttgtaata	atgcattttc	agagttggat	tgtagccttg	ttggtaaagc	aaattcttag	6120
ccacaaagaa	tctctgggtcc	gtgcaaattc	tgaattagct	ttcaaagtgc	ctagagtaga	6180
ggtggattat	atttattcga	tattgtcctg	catgaagagt	ctgttcctgg	agcatacaca	6240
aggtttgcag	ttcgattgct	ttggtactaa	ttctaaacag	tcagtgggta	gcacaaaact	6300
agtaaatgaa	agtctctcag	gggtacagt	gcgtgacgaa	aagattaata	cgaagtcgat	6360
gcgaaatagc	tcagaggatg	aagagtgcac	gactgagaag	agatgtagcc	attatagcac	6420
agcaacaaga	gatatcgaaa	agactattag	tggcataaaa	aagaaataca	agaagcaagt	6480
gcaaaaagctt	gtacaagagc	atgaggaaaa	gaaaatggag	ctgttaaata	tgtagtcaga	6540
caagaagcag	aaacttgaaa	ctagtaaaag	tgtggaagca	gcagtaattc	gtattacctg	6600
ttcacggacc	agtactcaag	tgggtgatct	caaactgctg	gatcataatt	atgaaagaaa	6660
gtttgatgaa	atcaaaagtg	agaaaaatga	atgcctcaa	agtctggagc	aatgcacga	6720
ggttgcaaag	aagaagttgg	ctgaggatga	agcctgttgg	attaatcgga	taaagagctg	6780
ggcagctaaa	ttaaaagttt	gtgttcccat	tcaaagtggc	aataacaagc	atttttagtgg	6840
ttcatcaaac	atttcccaaa	atgctcctga	tgtacaaatt	tgcaataatg	ctaacgttga	6900
agctacttac	gctgatacga	attgcatggc	ttccaagggt	aatcaagtgc	cagaagcaga	6960
aaacacatta	ggaaccatgt	cgggtggcag	cactcaacaa	gttcatgaaa	tggtggatgt	7020
aagaaatgac	gagacaatgg	atgtctcagc	tttgtctcgt	gaacagctta	caaagagcca	7080
gtccaatgag	cacgcttcta	tcactgtgcc	tgagattttg	attcctgctg	actgtcaaga	7140
ggaatttgcg	gccttgaaag	tgcatttgct	agaagaccag	aattgtgaca	gaataacatc	7200
tgccgcatca	gatgaagatg	tttcatcaag	ggtgccagag	gtatcccagt	cactcgaaaa	7260
tctttctgcc	tcccccgagt	tttctctaaa	tagagaggag	gctttgggta	caacagaaaa	7320
tagaagaaca	agtcatgtgg	gttttgatac	tgataacatt	ttggaccagc	agaatagaga	7380
agattgttct	cttgaccaag	agattcctga	cgagtttagc	atgcctgtgc	aacatcttgc	7440
gtctgtggta	gagactaggg	gtgctgctga	atctgatcag	gtacttactg	gccctgtaga	7500
atagttgatg	ccttgttcat	ttaatctttt	ctaattgtca	ttcttgcttt	cttgaaaata	7560
acgggtagtg	atcagatgtc	ttttttctc	ttattaaatt	cacttttctg	gacagtattg	7620
tcaagatata	tgtcctatgc	cttcttcaact	ggctggaaag	caacctgacc	cagcagcaaa	7680
cactgagagc	gaaaatcttg	aagaagcaat	tgagcctcag	tctgctgggt	cagaaacagt	7740
agagactact	gattttgctg	catcacatca	ggtccctatt	gaagactttc	cttttttact	7800
agtttaaagt	tatcaatctg	tgttatgttc	attctaagtt	tccgtgagaa	aaaggtgggg	7860
aaatgtgggt	actgatcaag	tctcggtgtt	gttttaaatc	gactcttttg	acaggggtgat	7920
caagttacat	gtcctttgct	atcttcaccg	actggaaatc	agcctgcgcc	agaagcaaat	7980
attgaaggcc	aaaatatcaa	cacatcagct	gagccccatg	tagcgggtcc	agatgcagta	8040

```
<400> 2
cacaagcatg agtttttccct tccggtaatc gtaaaatcaa aaatcgctcg ctgagaaaac 60
gccggtgcta gaagagggaaa gtaccgtaca taatcctgcg aaccaattc tcgtcttttt 120
```

caaactcagt	tttccgaaac	cccaaacacc	gcgaggattg	catggcctga	agaaccactt	180
aatcgagaat	tgtgctggaa	ttctcaaatt	ttccctcgcg	tttttctttc	acactctcgg	240
aatcgaaaat	ttccaccaag	ctccgtcaag	cgatagattc	tgacaattac	acactttcgc	300
gcagtgaat	atg aag aaa	gat gaa aag	att ggt ttg	acg ggg aga	acc att	351
	Met Lys Lys	Asp Glu Lys	Ile Gly Leu	Thr Gly Arg	Thr Ile	
	1	5		10		
tac acc aga	tcc cta gca	gct tca att	cct gcc tca	ggt gaa caa	gaa	399
Tyr Thr Arg	Ser Leu Ala	Ala Ser Ile	Pro Ala Ser	Val Glu Gln	Glu	
15	20		25	30		
acc cct ggt	ttg agg agg	tca agc cgg	ggg aca cca	tct acg aag	gta	447
Thr Pro Gly	Leu Arg Arg	Ser Ser Arg	Gly Thr Pro	Ser Thr Lys	Val	
	35		40	45		
ata act cca	gct tct gct	act aga aag	tca gag aga	ctg gct ccc	tca	495
Ile Thr Pro	Ala Ser Ala	Thr Arg Lys	Ser Glu Arg	Leu Ala Pro	Ser	
	50		55	60		
cct gct tca	ggt tca aaa	aag tcc ggt	gga atc gtc	aag aat tcc	aca	543
Pro Ala Ser	Val Ser Lys	Lys Ser Gly	Gly Ile Val	Lys Asn Ser	Thr	
	65		70	75		
cca agt tct	ttg cga agg	tcc aat agg	ggg aag act	gaa gta tcc	ttg	591
Pro Ser Ser	Leu Arg Arg	Ser Asn Arg	Gly Lys Thr	Glu Val Ser	Leu	
	80		85	90		
cag agt tcc	aaa gga tca	gat aat tct	atc agg aaa	gga gat act	tca	639
Gln Ser Ser	Lys Gly Ser	Asp Asn Ser	Ile Arg Lys	Gly Asp Thr	Ser	
	95		100	105		
ccg gat att	gag cag aga	aag gat agt	ggt gaa gag	tcg aca gat	aag	687
Pro Asp Ile	Glu Gln Arg	Lys Asp Ser	Val Glu Glu	Ser Thr Asp	Lys	
	115		120	125		
atc aag cct	ata atg tca	gcc cga agt	tac agg gca	ttg ttt aga	ggg	735
Ile Lys Pro	Ile Met Ser	Ala Arg Ser	Tyr Arg Ala	Leu Phe Arg	Gly	
	130		135	140		
aag ctc aag	gaa tct gag	gca tta gtt	gat gct tcc	cca aat gaa	gag	783
Lys Leu Lys	Glu Ser Glu	Ala Leu Val	Asp Ala Ser	Pro Asn Glu	Glu	
	145		150	155		
gaa cta gta	ggt gtt ggt	tgt tct cgc	cgc ata cct	gca ggc aat	gat	831
Glu Leu Val	Val Val Val	Gly Cys Ser	Arg Arg Ile	Pro Ala Gly	Asn Asp	
	160		165	170		
gat gtt caa	ggg aaa aca	gat tgt cca	cca cct gca	gat gca gga	tca	879
Asp Val Gln	Gly Lys Thr	Asp Cys Pro	Pro Pro Ala	Asp Ala Gly	Ser	
	175		180	185		
aaa agg ctg	cca gtt gac	gaa act agt	ttg gac aag	ggc act gat	ttt	927



WO 01/00801

PCT/EP00/05761

- 8 -

cgg caa aag gtc aac ggt gat tgt caa aat agg agt gtt tgc tcc tgc	1599
Arg Gln Lys Val Asn Gly Asp Cys Gln Asn Arg Ser Val Cys Ser Cys	
415 420 425 430	
att gtc cag cca gtt gaa gaa tct gat aac gtg aca cag gat atg aaa	1647
Ile Val Gln Pro Val Glu Glu Ser Asp Asn Val Thr Gln Asp Met Lys	
435 440 445	
gaa act gga cca gtt acg agc aga gaa tat gag gag aac ggg caa ata	1695
Glu Thr Gly Pro Val Thr Ser Arg Glu Tyr Glu Glu Asn Gly Gln Ile	
450 455 460	
caa cat ggt aaa tca agt gat ccc aaa ttc tat tct tcg gtg tac cca	1743
Gln His Gly Lys Ser Ser Asp Pro Lys Phe Tyr Ser Ser Val Tyr Pro	
465 470 475	
gag tat tgg gtt cct gtg cag cta tca gat gta cag ctg gag caa tac	1791
Glu Tyr Trp Val Pro Val Gln Leu Ser Asp Val Gln Leu Glu Gln Tyr	
480 485 490	
tgt cag act ctc ttc tcc aaa tcc tta tct ctt tct tca ctt tcg aag	1839
Cys Gln Thr Leu Phe Ser Lys Ser Leu Ser Leu Ser Ser Leu Ser Lys	
495 500 505 510	
att gat ctt gga gct cta gaa gaa act ctc aat tct gta aga aaa acc	1887
Ile Asp Leu Gly Ala Leu Glu Glu Thr Leu Asn Ser Val Arg Lys Thr	
515 520 525	
tgt gac cat cca tac gtt atg gat gca tct ttg aaa caa ctg ctc acc	1935
Cys Asp His Pro Tyr Val Met Asp Ala Ser Leu Lys Gln Leu Leu Thr	
530 535 540	
aag aat ctg gag ttg cat gaa atc ctg gat gta gaa att aaa gcg agc	1983
Lys Asn Leu Glu Leu His Glu Ile Leu Asp Val Glu Ile Lys Ala Ser	
545 550 555	
ggg aaa ctt cac ctc ctt gat aaa atg ctt act cat ata aaa aag aat	2031
Gly Lys Leu His Leu Leu Asp Lys Met Leu Thr His Ile Lys Lys Asn	
560 565 570	
ggt tta aaa gca gtt gtc ttc tac cag gca aca caa acc cct gaa ggg	2079
Gly Leu Lys Ala Val Val Phe Tyr Gln Ala Thr Gln Thr Pro Glu Gly	
575 580 585 590	
ctt ctg ctt ggt aat att ctc gaa gat ttt gtg ggt caa aga ttt ggt	2127
Leu Leu Leu Gly Asn Ile Leu Glu Asp Phe Val Gly Gln Arg Phe Gly	
595 600 605	
cca aaa tct tat gag cat ggg ata tat tcc tca aag aag aac tcc gct	2175
Pro Lys Ser Tyr Glu His Gly Ile Tyr Ser Ser Lys Lys Asn Ser Ala	
610 615 620	
ata aac aat ttc aac aag gag agt caa tgc tgt gtt ctg ctg ttg gaa	2223
Ile Asn Asn Phe Asn Lys Glu Ser Gln Cys Cys Val Leu Leu Leu Glu	
625 630 635	

aca	cgt	gcc	tgc	agt	caa	acc	att	aaa	ctc	ttg	cga	gct	gat	gcg	ttt	2271
Thr	Arg	Ala	Cys	Ser	Gln	Thr	Ile	Lys	Leu	Leu	Arg	Ala	Asp	Ala	Phe	
640						645					650					
att	ctt	ttt	gga	agc	agc	ttg	aat	cca	tcg	cat	gat	gtt	aag	cac	gta	2319
Ile	Leu	Phe	Gly	Ser	Ser	Leu	Asn	Pro	Ser	His	Asp	Val	Lys	His	Val	
655					660					665					670	
gag	aag	ata	aaa	atc	gag	tca	tgt	tct	gaa	aga	act	aag	ata	ttc	cga	2367
Glu	Lys	Ile	Lys	Ile	Glu	Ser	Cys	Ser	Glu	Arg	Thr	Lys	Ile	Phe	Arg	
				675					680					685		
ttg	tac	tca	gta	tgt	aca	gtt	gaa	gaa	aaa	gcc	ctg	att	ctg	gct	agg	2415
Leu	Tyr	Ser	Val	Cys	Thr	Val	Glu	Glu	Lys	Ala	Leu	Ile	Leu	Ala	Arg	
			690					695					700			
caa	aat	atg	cgg	caa	aat	aaa	gct	gta	gag	aac	cta	aac	cgc	tct	ctc	2463
Gln	Asn	Met	Arg	Gln	Asn	Lys	Ala	Val	Glu	Asn	Leu	Asn	Arg	Ser	Leu	
		705					710					715				
acg	cac	gca	ctg	ctc	atg	tgg	ggg	gcg	tca	tac	tta	ttt	gat	aaa	ctg	2511
Thr	His	Ala	Leu	Leu	Met	Trp	Gly	Ala	Ser	Tyr	Leu	Phe	Asp	Lys	Leu	
	720					725					730					
gat	cat	ttt	cac	agc	agt	gaa	act	cca	gat	tca	gga	ggt	tca	ttt	gaa	2559
Asp	His	Phe	His	Ser	Ser	Glu	Thr	Pro	Asp	Ser	Gly	Val	Ser	Phe	Glu	
735					740				745						750	
caa	tct	att	atg	gac	ggc	gtg	att	cat	gaa	ttc	tcg	tcc	ata	ctt	tct	2607
Gln	Ser	Ile	Met	Asp	Gly	Val	Ile	His	Glu	Phe	Ser	Ser	Ile	Leu	Ser	
				755					760					765		
tcc	aaa	ggt	gga	gaa	gaa	aat	gaa	gtc	aag	ctg	tgt	cta	ctt	ttg	gag	2655
Ser	Lys	Gly	Gly	Glu	Glu	Asn	Glu	Val	Lys	Leu	Cys	Leu	Leu	Leu	Glu	
			770					775					780			
gcc	aag	cat	gct	cag	gga	act	tac	agc	agt	gat	tct	act	cta	ttt	ggt	2703
Ala	Lys	His	Ala	Gln	Gly	Thr	Tyr	Ser	Ser	Asp	Ser	Thr	Leu	Phe	Gly	
		785					790					795				
gaa	gac	cat	att	aag	ttg	tca	gat	gaa	gag	agt	cca	aat	ata	ttt	tgg	2751
Glu	Asp	His	Ile	Lys	Leu	Ser	Asp	Glu	Glu	Ser	Pro	Asn	Ile	Phe	Trp	
	800					805					810					
tca	aag	ctg	ttg	ggg	gga	aaa	aat	cct	atg	tgg	aaa	tac	cct	tca	gat	2799
Ser	Lys	Leu	Leu	Gly	Gly	Lys	Asn	Pro	Met	Trp	Lys	Tyr	Pro	Ser	Asp	
	815				820					825					830	
act	ccc	caa	agg	aat	cga	aaa	cga	gtt	cag	tat	ttt	gag	ggt	tct	gaa	2847
Thr	Pro	Gln	Arg	Asn	Arg	Lys	Arg	Val	Gln	Tyr	Phe	Glu	Gly	Ser	Glu	
</																



850							855					860					
gct	tct	gat	gat	gtc	act	gat	ccc	cgg	gtc	act	gat	ccg	cca	gta	gat	2943	
Ala	Ser	Asp	Asp	Val	Thr	Asp	Pro	Arg	Val	Thr	Asp	Pro	Pro	Val	Asp		
865							870					875					
gat	gat	gaa	aga	aag	gcc	tct	ggg	aag	gat	cac	atg	ggg	gct	ttg	gag	2991	
Asp	Asp	Glu	Arg	Lys	Ala	Ser	Gly	Lys	Asp	His	Met	Gly	Ala	Leu	Glu		
880							885					890					
tca	cca	aaa	gtc	ata	aca	ctc	cag	tca	tca	tgt	aaa	tct	tct	ggt	aca	3039	
Ser	Pro	Lys	Val	Ile	Thr	Leu	Gln	Ser	Ser	Cys	Lys	Ser	Ser	Gly	Thr		
895							900					905					
gat	ggt	aca	ttg	gat	gga	aat	gat	gct	ttt	ggc	ttg	tat	tct	atg	ggc	3087	
Asp	Gly	Thr	Leu	Asp	Gly	Asn	Asp	Ala	Phe	Gly	Leu	Tyr	Ser	Met	Gly		
915							920					925					
agc	cat	atc	tct	gga	atc	cca	gag	gat	atg	tta	gct	agt	caa	gat	tgg	3135	
Ser	His	Ile	Ser	Gly	Ile	Pro	Glu	Asp	Met	Leu	Ala	Ser	Gln	Asp	Trp		
930							935					940					
ggg	aaa	ata	ccg	gat	gaa	tca	cag	agg	agg	ctc	cac	act	gtt	tta	aag	3183	
Gly	Lys	Ile	Pro	Asp	Glu	Ser	Gln	Arg	Arg	Leu	His	Thr	Val	Leu	Lys		
945							950					955					
ccg	aag	atg	gca	aaa	ctt	tgc	caa	gtt	ttg	cat	ctt	tca	gat	gct	tgc	3231	
Pro	Lys	Met	Ala	Lys	Leu	Cys	Gln	Val	Leu	His	Leu	Ser	Asp	Ala	Cys		
960							965					970					
aca	agc	atg	gtc	gga	aat	ttt	ctc	gaa	tat	gtt	att	gaa	aat	cac	cga	3279	
Thr	Ser	Met	Val	Gly	Asn	Phe	Leu	Glu	Tyr	Val	Ile	Glu	Asn	His	Arg		
975							980					985					
atc	tac	gaa	gag	cca	gcc	act	act	ttt	cag	gca	ttc	cag	ata	gcc	ctg	3327	
Ile	Tyr	Glu	Glu	Pro	Ala	Thr	Thr	Phe	Gln	Ala	Phe	Gln	Ile	Ala	Leu		
995							1000					1005					
agt	tgg	att	gca	gcc	ttg	ttg	gta	aag	caa	att	ctt	agc	cac	aaa	gaa	3375	
Ser	Trp	Ile	Ala	Ala	Leu	Leu	Val	Lys	Gln	Ile	Leu	Ser	His	Lys	Glu		
1010							1015					1020					
tct	ctg	gtc	cgt	gca	aat	tct	gaa	tta	gct	ttc	aaa	tgc	tct	aga	gta	3423	
Ser	Leu	Val	Arg	Ala	Asn	Ser	Glu	Leu	Ala	Phe	Lys	Cys	Ser	Arg	Val		
1025							1030					1035					
gag	gtg	gat	tat	att	tat	tcg	ata	ttg	tcc	tgc	atg	aag	agt	ctg	ttc	3471	
Glu	Val	Asp	Tyr	Ile	Tyr	Ser	Ile	Leu	Ser	Cys	Met	Lys	Ser	Leu	Phe		
1040							1045					1050					
ctg	gag	cat	aca	caa	ggt	ttg	cag	ttc	gat	tgc	ttt	ggt	act	aat	tct	3519	
Leu	Glu	His	Thr	Gln	Gly	Leu	Gln	Phe	Asp	Cys	Phe	Gly	Thr	Asn	Ser		
1055							1060					1065					
aaa	cag	tca	gtg	gtt	agc	aca	aaa	cta	gta	aat	gaa	agt	ctc	tca	ggg	3567	

WO 01/00801

PCT/EP00/05761

- 11 -

Lys Gln Ser Val Val Ser Thr Lys Leu Val Asn Glu Ser Leu Ser Gly	
1075 1080 1085	
gct aca gtg cgt gac gaa aag att aat acg aag tcg atg cga aat agc	3615
Ala Thr Val Arg Asp Glu Lys Ile Asn Thr Lys Ser Met Arg Asn Ser	
1090 1095 1100	
tca gag gat gaa gag tgc atg act gag aag aga tgt agc cat tat agc	3663
Ser Glu Asp Glu Glu Cys Met Thr Glu Lys Arg Cys Ser His Tyr Ser	
1105 1110 1115	
aca gca aca aga gat atc gaa aag act att agt ggc ata aaa aag aaa	3711
Thr Ala Thr Arg Asp Ile Glu Lys Thr Ile Ser Gly Ile Lys Lys Lys	
1120 1125 1130	
tac aag aag caa gtg caa aag ctt gta caa gag cat gag gaa aag aaa	3759
Tyr Lys Lys Gln Val Gln Lys Leu Val Gln Glu His Glu Glu Lys Lys	
1135 1140 1145 1150	
atg gag ctg tta aat atg tat gca gac aag aag cag aaa ctt gaa act	3807
Met Glu Leu Leu Asn Met Tyr Ala Asp Lys Lys Gln Lys Leu Glu Thr	
1155 1160 1165	
agt aaa agt gtg gaa gca gca gta att cgt att acc tgt tca cgg acc	3855
Ser Lys Ser Val Glu Ala Ala Val Ile Arg Ile Thr Cys Ser Arg Thr	
1170 1175 1180	
agt act caa gtg ggt gat ctc aaa ctg ctg gat cat aat tat gaa aga	3903
Ser Thr Gln Val Gly Asp Leu Lys Leu Leu Asp His Asn Tyr Glu Arg	
1185 1190 1195	
aag ttt gat gaa atc aaa agt gag aaa aat gaa tgc ctc aaa agt ctg	3951
Lys Phe Asp Glu Ile Lys Ser Glu Lys Asn Glu Cys Leu Lys Ser Leu	
1200 1205 1210	
gag caa atg cac gag gtt gca aag aag aag ttg gct gag gat gaa gcc	3999
Glu Gln Met His Glu Val Ala Lys Lys Lys Leu Ala Glu Asp Glu Ala	
1215 1220 1225 1230	
tgt tgg att aat cgg ata aag agc tgg gca gct aaa tta aaa gtt tgt	4047
Cys Trp Ile Asn Arg Ile Lys Ser Trp Ala Ala Lys Leu Lys Val Cys	
1235 1240 1245	
gtt ccc att caa agt ggc aat aac aag cat ttt agt ggt tca tca aac	4095
Val Pro Ile Gln Ser Gly Asn Asn Lys His Phe Ser Gly Ser Ser Asn	
1250 1255 1260	
att tcc caa aat gct cct gat gta caa att tgc aat aat gct aac gtt	4143
Ile Ser Gln Asn Ala Pro Asp Val Gln Ile Cys Asn Asn Ala Asn Val	
1265 1270 1275	
gaa gct act tac gct gat acg aat tgc atg gct tcc aag gtt aat caa	4191
Glu Ala Thr Tyr Ala Asp Thr Asn Cys Met Ala Ser Lys Val Asn Gln	
1280 1285 1290	

WO 01/00801

PCT/EP00/05761

- 12 -

gtg cca gaa gca gaa aac aca tta gga acc atg tcg ggt ggc agc act	4239
Val Pro Glu Ala Glu Asn Thr Leu Gly Thr Met Ser Gly Gly Ser Thr	
1295                      1300                      1305                      1310	
caa caa gtt cat gaa atg gtg gat gta aga aat gac gag aca atg gat	4287
Gln Gln Val His Glu Met Val Asp Val Arg Asn Asp Glu Thr Met Asp	
1315                      1320                      1325	
gtc tca gct ttg tct cgt gaa cag ctt aca aag agc cag tcc aat gag	4335
Val Ser Ala Leu Ser Arg Glu Gln Leu Thr Lys Ser Gln Ser Asn Glu	
1330                      1335                      1340	
cac gct tct atc act gtg cct gag att ttg att cct gct gac tgt caa	4383
His Ala Ser Ile Thr Val Pro Glu Ile Leu Ile Pro Ala Asp Cys Gln	
1345                      1350                      1355	
gag gaa ttt gcg gcc ttg aac gtg cat ttg tca gaa gac cag aat tgt	4431
Glu Glu Phe Ala Ala Leu Asn Val His Leu Ser Glu Asp Gln Asn Cys	
1360                      1365                      1370	
gac aga ata aca tct gcg gca tca gat gaa gat gtt tca tca agg gtg	4479
Asp Arg Ile Thr Ser Ala Ala Ser Asp Glu Asp Val Ser Ser Arg Val	
1375                      1380                      1385                      1390	
cca gag gta tcc cag tca ctc gaa aat ctt tct gcc tcc ccc gag ttt	4527
Pro Glu Val Ser Gln Ser Leu Glu Asn Leu Ser Ala Ser Pro Glu Phe	
1395                      1400                      1405	
tct cta aat aga gag gag gct ttg gtt aca aca gaa aat aga aga aca	4575
Ser Leu Asn Arg Glu Glu Ala Leu Val Thr Thr Glu Asn Arg Arg Thr	
1410                      1415                      1420	
agt cat gtg ggt ttt gat act gat aac att ttg gac cag cag aat aga	4623
Ser His Val Gly Phe Asp Thr Asp Asn Ile Leu Asp Gln Gln Asn Arg	
1425                      1430                      1435	
gaa gat tgt tct ctt gac caa gag att cct gac gag tta gcg atg cct	4671
Glu Asp Cys Ser Leu Asp Gln Glu Ile Pro Asp Glu Leu Ala Met Pro	
1440                      1445                      1450	
gtg caa cat ctt gcg tct gtg gta gag act agg ggt gct gct gaa tct	4719
Val Gln His Leu Ala Ser Val Val Glu Thr Arg Gly Ala Ala Glu Ser	
1455                      1460                      1465                      1470	
gat cag tat ggt caa gat ata tgt cct atg cct tct tca ctg gct gga	4767
Asp Gln Tyr Gly Gln Asp Ile Cys Pro Met Pro Ser Ser Leu Ala Gly	
1475                      1480                      1485	
aag caa cct gac cca gca gca aac act gag agc gaa aat ctt gaa gaa	4815
Lys Gln Pro Asp Pro Ala Ala Asn Thr Glu Ser Glu Asn Leu Glu Glu	
1490                      1495                      1500	
gca att gag cct cag tct gct ggt tca gaa aca gta gag act act gat	4863
Ala Ile Glu Pro Gln Ser Ala Gly Ser Glu Thr Val Glu Thr Thr Asp	
1505                      1510                      1515	

WO 01/00801

PCT/EP00/05761

- 13 -

ttt gct gca tca cat cag ggt gat caa gtt aca tgt cct ttg cta tct	4911
Phe Ala Ala Ser His Gln Gly Asp Gln Val Thr Cys Pro Leu Leu Ser	
1520 1525 1530	
tca ccg act gga aat cag cct gcg cca gaa gca aat att gaa ggc caa	4959
Ser Pro Thr Gly Asn Gln Pro Ala Pro Glu Ala Asn Ile Glu Gly Gln	
1535 1540 1545 1550	
aat atc aac aca tca gct gag ccc cat gta gcg ggt cca gat gca gta	5007
Asn Ile Asn Thr Ser Ala Glu Pro His Val Ala Gly Pro Asp Ala Val	
1555 1560 1565	
gag agt ggt gat tat gca gta ata gat cag gaa aca atg ggt gct cag	5055
Glu Ser Gly Asp Tyr Ala Val Ile Asp Gln Glu Thr Met Gly Ala Gln	
1570 1575 1580	
gat gca tgc tct ctg cca tct gga tcg gtt gga act cag tct gac cta	5103
Asp Ala Cys Ser Leu Pro Ser Gly Ser Val Gly Thr Gln Ser Asp Leu	
1585 1590 1595	
gga gca aac att gag ggt caa aat gtc aca aca gtg gct caa ctt ccc	5151
Gly Ala Asn Ile Glu Gly Gln Asn Val Thr Thr Val Ala Gln Leu Pro	
1600 1605 1610	
aca gat gga tca gat gca gtt gta acc ggt gga tct cct gta tca gat	5199
Thr Asp Gly Ser Asp Ala Val Val Thr Gly Gly Ser Pro Val Ser Asp	
1615 1620 1625 1630	
cag tgt gcc cag gat gca tct cct atg cca tta tct tcg cct gga aat	5247
Gln Cys Ala Gln Asp Ala Ser Pro Met Pro Leu Ser Ser Pro Gly Asn	
1635 1640 1645	
cac cct gat aca gca gtt aat atc gag ggt tta gat aac aca tca gta	5295
His Pro Asp Thr Ala Val Asn Ile Glu Gly Leu Asp Asn Thr Ser Val	
1650 1655 1660	
gct gag cct cat ata agt gga tca gat gca tgt gaa atg gaa att tca	5343
Ala Glu Pro His Ile Ser Gly Ser Asp Ala Cys Glu Met Glu Ile Ser	
1665 1670 1675	
gaa cct ggt ccc caa gta gag cgg tca acc ttt gca aat ctt ttc cat	5391
Glu Pro Gly Pro Gln Val Glu Arg Ser Thr Phe Ala Asn Leu Phe His	
1680 1685 1690	
gaa ggt ggc gtg gag cat tca gca ggt gta aca gct ctt gtt cca tca	5439
Glu Gly Gly Val Glu His Ser Ala Gly Val Thr Ala Leu Val Pro Ser	
1695 1700 1705 1710	
ctt ctt aac aat ggt acg gaa cag att gcc gtt caa cct gtt cct caa	5487
Leu Leu Asn Asn Gly Thr Glu Gln Ile Ala Val Gln Pro Val Pro Gln	
1715 1720 1725	
ata cct ttc cct gtg ttc aac gac ccg ttt ctg cat gaa ctg gag aag	5535
Ile Pro Phe Pro Val Phe Asn Asp Pro Phe Leu His Glu Leu Glu Lys	

WO 01/00801

PCT/EP00/05761

- 14 -

1730	1735	1740	
ttg cgg aga gaa tca gag aac tca aag aag act ttt gaa gaa aaa aaa			5583
Leu Arg Arg Glu Ser Glu Asn Ser Lys Lys Thr Phe Glu Glu Lys Lys			
1745	1750	1755	
tca atc ttg aaa gct gaa ctc gag agg aag atg gct gaa gta caa gca			5631
Ser Ile Leu Lys Ala Glu Leu Glu Arg Lys Met Ala Glu Val Gln Ala			
1760	1765	1770	
gag ttt cga aga aaa ttt cat gag gta gaa gcc gag cat aac acc aga			5679
Glu Phe Arg Arg Lys Phe His Glu Val Glu Ala Glu His Asn Thr Arg			
1775	1780	1785	1790
acg aca aag ata gag aag gat aag aat ctt gtt ata atg aac aaa ctg			5727
Thr Thr Lys Ile Glu Lys Asp Lys Asn Leu Val Ile Met Asn Lys Leu			
1795	1800	1805	
ttg gcg aat gcg ttc ttg tcc aaa tgt act gac aag aag gta tct ccc			5775
Leu Ala Asn Ala Phe Leu Ser Lys Cys Thr Asp Lys Lys Val Ser Pro			
1810	1815	1820	
tca gga gct cca agg ggt aaa att cag cag cta gca cag aga gca gca			5823
Ser Gly Ala Pro Arg Gly Lys Ile Gln Gln Leu Ala Gln Arg Ala Ala			
1825	1830	1835	
caa gtg agt gca ctg aga aat tac att gct cct cag cag ctt cag gca			5871
Gln Val Ser Ala Leu Arg Asn Tyr Ile Ala Pro Gln Gln Leu Gln Ala			
1840	1845	1850	
tct tct ttt cct gct cct gct ctg gtt tcg gct cct ctg caa ctt cag			5919
Ser Ser Phe Pro Ala Pro Ala Leu Val Ser Ala Pro Leu Gln Leu Gln			
1855	1860	1865	1870
caa tca tca ttt cct gct cct ggt ccg gct cct ctg cag cct cag gca			5967
Gln Ser Ser Phe Pro Ala Pro Gly Pro Ala Pro Leu Gln Pro Gln Ala			
1875	1880	1885	
tct tcg ttt cct tct tca gtc tct cgt cca tca gcc ctt ctt ctg aat			6015
Ser Ser Phe Pro Ser Ser Val Ser Arg Pro Ser Ala Leu Leu Leu Asn			
1890	1895	1900	
ttt gcg gtc tgt cca atg cct cag ccc aga cag cct ctc ata tcc aac			6063
Phe Ala Val Cys Pro Met Pro Gln Pro Arg Gln Pro Leu Ile Ser Asn			
1905	1910	1915	
ata gct cca act cca tca gtt act cct gca aca aat cca ggt ctg cgt			6111
Ile Ala Pro Thr Pro Ser Val Thr Pro Ala Thr Asn Pro Gly Leu Arg			
1920	1925	1930	
tct cct gca cca cac cta aac tca tat aga cca tcc tct tca act ccc			6159
Ser Pro Ala Pro His Leu Asn Ser Tyr Arg Pro Ser Ser Ser Thr Pro			
1935	1940	1945	1950
gtc gcc aca gct act cca acc tcg tca gtg cct cct caa gct ttg aca			6207

WO 01/00801

PCT/EP00/05761

- 15 -

Val Ala Thr Ala Thr Pro Thr Ser Ser Val Pro Pro Gln Ala Leu Thr  
1955 1960 1965

tat tca gct gtg tca att cag cag cag caa gaa caa caa ccg caa cag 6255  
Tyr Ser Ala Val Ser Ile Gln Gln Gln Gln Glu Gln Gln Pro Gln Gln  
1970 1975 1980

agc ttg agc agt gga ttg cag agc aac aat gaa gtg gtt tgt ctt tct 6303  
Ser Leu Ser Ser Gly Leu Gln Ser Asn Asn Glu Val Val Cys Leu Ser  
1985 1990 1995

gac gac gag tgacctaaga ggagagatgg ttaggggtctt agttattgat 6352  
Asp Asp Glu  
2000

ttttagagag ttaataatag tatatatata tatgtataag taggttacct aatctctgtc 6412

gttaaatctaa tttagtgagt caggaaccga ctcgttggct aaggtctctc cttttgaaac 6472

gcaacgttct actttcatgt atataaatac agtctgatca cacaacacaa attgatgatt 6532

gaaaatacta ctgatttaac ttaaaaaaaaa aaaaaaaaaa 6571

<210> 3  
<211> 2001  
<212> PRT  
<213> Arabidopsis thaliana

<400> 3  
Met Lys Lys Asp Glu Lys Ile Gly Leu Thr Gly Arg Thr Ile Tyr Thr  
1 5 10 15

Arg Ser Leu Ala Ala Ser Ile Pro Ala Ser Val Glu Gln Glu Thr Pro  
20 25 30

Gly Leu Arg Arg Ser Ser Arg Gly Thr Pro Ser Thr Lys Val Ile Thr  
35 40 45

Pro Ala Ser Ala Thr Arg Lys Ser Glu Arg Leu Ala Pro Ser Pro Ala  
50 55 60

Ser Val Ser Lys Lys Ser Gly Gly Ile Val Lys Asn Ser Thr Pro Ser  
65 70 75 80

Ser Leu Arg Arg Ser Asn Arg Gly Lys Thr Glu Val Ser Leu Gln Ser  
85 90 95

Ser Lys Gly Ser Asp Asn Ser Ile Arg Lys Gly Asp Thr Ser Pro Asp  
100 105 110

Ile Glu Gln Arg Lys Asp Ser Val Glu Glu Ser Thr Asp Lys Ile Lys  
115 120 125

Pro Ile Met Ser Ala Arg Ser Tyr Arg Ala Leu Phe Arg Gly Lys Leu

WO 01/00801

PCT/EP00/05761

- 16 -

130	135	140
Lys Glu Ser Glu Ala Leu Val Asp Ala Ser Pro Asn Glu Glu Glu Leu		
145	150	155
Val Val Val Gly Cys Ser Arg Arg Ile Pro Ala Gly Asn Asp Asp Val		
	165	170
Gln Gly Lys Thr Asp Cys Pro Pro Pro Ala Asp Ala Gly Ser Lys Arg		
	180	185
Leu Pro Val Asp Glu Thr Ser Leu Asp Lys Gly Thr Asp Phe Pro Leu		
	195	200
Lys Ser Val Thr Glu Thr Glu Lys Ile Val Leu Asp Ala Ser Pro Ile		
	210	215
Val Glu Thr Gly Asp Asp Ser Val Ile Gly Ser Pro Ser Glu Asn Leu		
	225	230
Glu Thr Gln Lys Leu Gln Asp Gly Lys Thr Asp Cys Ser Pro Pro Ala		
	245	250
Asn Ala Glu Ser Lys Thr Leu Pro Val Gly Glu Thr Ser Leu Glu Lys		
	260	265
Glu Tyr Pro Gln Lys Phe Gln Asp Asp Asn Thr Asp Cys Leu Pro Pro		
	275	280
Ala Asn Ala Glu Ser Lys Arg Leu Pro Val Gly Glu Thr Ser Leu Glu		
	290	295
Lys Asp Thr Asp Phe Pro Leu Lys Ser Thr Thr Glu Thr Gly Lys Met		
	305	310
Val Leu Tyr Ala Ser Pro Ile Val Glu Thr Arg Asp Asp Ser Val Ile		
	325	330
Cys Ser Pro Ser Thr Asn Leu Glu Thr Gln Lys Leu Leu Val Ser Lys		
	340	345
Thr Gly Leu Glu Thr Asp Ile Val Leu Pro Leu Lys Arg Lys Arg Asp		
	355	360
Thr Ala Glu Ile Glu Leu Asp Ala Cys Ala Thr Val Ala Asn Gly Asp		
	370	375
Asp His Val Met Ser Ser Asp Gly Val Ile Pro Ser Pro Ser Gly Cys		
	385	390
Lys Asn Asp Asn Arg Pro Glu Met Cys Asn Thr Cys Lys Lys Arg Gln		
	405	410
Lys Val Asn Gly Asp Cys Gln Asn Arg Ser Val Cys Ser Cys Ile Val		
	420	425
		430

WO 01/00801

PCT/EP00/05761

- 17 -

Gln Pro Val Glu Glu Ser Asp Asn Val Thr Gln Asp Met Lys Glu Thr  
435 440 445

Gly Pro Val Thr Ser Arg Glu Tyr Glu Glu Asn Gly Gln Ile Gln His  
450 455 460

Gly Lys Ser Ser Asp Pro Lys Phe Tyr Ser Ser Val Tyr Pro Glu Tyr  
465 470 475 480

Trp Val Pro Val Gln Leu Ser Asp Val Gln Leu Glu Gln Tyr Cys Gln  
485 490 495

Thr Leu Phe Ser Lys Ser Leu Ser Leu Ser Ser Leu Ser Lys Ile Asp  
500 505 510

Leu Gly Ala Leu Glu Glu Thr Leu Asn Ser Val Arg Lys Thr Cys Asp  
515 520 525

His Pro Tyr Val Met Asp Ala Ser Leu Lys Gln Leu Leu Thr Lys Asn  
530 535 540

Leu Glu Leu His Glu Ile Leu Asp Val Glu Ile Lys Ala Ser Gly Lys  
545 550 555 560

Leu His Leu Leu Asp Lys Met Leu Thr His Ile Lys Lys Asn Gly Leu  
565 570 575

Lys Ala Val Val Phe Tyr Gln Ala Thr Gln Thr Pro Glu Gly Leu Leu  
580 585 590

Leu Gly Asn Ile Leu Glu Asp Phe Val Gly Gln Arg Phe Gly Pro Lys  
595 600 605

Ser Tyr Glu His Gly Ile Tyr Ser Ser Lys Lys Asn Ser Ala Ile Asn  
610 615 620

Asn Phe Asn Lys Glu Ser Gln Cys Cys Val Leu Leu Leu Glu Thr Arg  
625 630 635 640

Ala Cys Ser Gln Thr Ile Lys Leu Leu Arg Ala Asp Ala Phe Ile Leu  
645 650 655

Phe Gly Ser Ser Leu Asn Pro Ser His Asp Val Lys His Val Glu Lys  
660 665 670

Ile Lys Ile Glu Ser Cys Ser Glu Arg Thr Lys Ile Phe Arg Leu Tyr  
675 680 685

Ser Val Cys Thr Val Glu Glu Lys Ala Leu Ile Leu Ala Arg Gln Asn  
690 695 700

Met Arg Gln Asn Lys Ala Val Glu Asn Leu Asn Arg Ser Leu Thr His  
705 710 715 720



WO 01/00801

PCT/EP00/05761

- 18 -

Ala Leu Leu Met Trp Gly Ala Ser Tyr Leu Phe Asp Lys Leu Asp His  
725 730 735

Phe His Ser Ser Glu Thr Pro Asp Ser Gly Val Ser Phe Glu Gln Ser  
740 745 750

Ile Met Asp Gly Val Ile His Glu Phe Ser Ser Ile Leu Ser Ser Lys  
755 760 765

Gly Gly Glu Glu Asn Glu Val Lys Leu Cys Leu Leu Leu Glu Ala Lys  
770 775 780

His Ala Gln Gly Thr Tyr Ser Ser Asp Ser Thr Leu Phe Gly Glu Asp  
785 790 795 800

His Ile Lys Leu Ser Asp Glu Glu Ser Pro Asn Ile Phe Trp Ser Lys  
805 810 815

Leu Leu Gly Gly Lys Asn Pro Met Trp Lys Tyr Pro Ser Asp Thr Pro  
820 825 830

Gln Arg Asn Arg Lys Arg Val Gln Tyr Phe Glu Gly Ser Glu Ala Ser  
835 840 845

Pro Lys Thr Gly Asp Gly Gly Asn Ala Lys Lys Arg Lys Lys Ala Ser  
850 855 860

Asp Asp Val Thr Asp Pro Arg Val Thr Asp Pro Pro Val Asp Asp Asp  
865 870 875 880

Glu Arg Lys Ala Ser Gly Lys Asp His Met Gly Ala Leu Glu Ser Pro  
885 890 895

Lys Val Ile Thr Leu Gln Ser Ser Cys Lys Ser Ser Gly Thr Asp Gly  
900 905 910

Thr Leu Asp Gly Asn Asp Ala Phe Gly Leu Tyr Ser Met Gly Ser His  
915 920 925

Ile Ser Gly Ile Pro Glu Asp Met Leu Ala Ser Gln Asp Trp Gly Lys  
930 935 940

Ile Pro Asp Glu Ser Gln Arg Arg Leu His Thr Val Leu Lys Pro Lys  
945 950 955 960

Met Ala Lys Leu Cys Gln Val Leu His Leu Ser Asp Ala Cys Thr Ser  
965 970 975

Met Val Gly Asn Phe Leu Glu Tyr Val Ile Glu Asn His Arg Ile Tyr  
980 985 990

Glu Glu Pro Ala Thr Thr Phe Gln Ala Phe Gln Ile Ala Leu Ser Trp  
995 1000 1005

Ile Ala Ala Leu Leu Val Lys Gln Ile Leu Ser His Lys Glu Ser Leu

1010	1015	1020
Val Arg Ala Asn Ser Glu Leu Ala Phe Lys Cys Ser Arg Val Glu Val 025 1030 1035 1040		
Asp Tyr Ile Tyr Ser Ile Leu Ser Cys Met Lys Ser Leu Phe Leu Glu 1045 1050 1055		
His Thr Gln Gly Leu Gln Phe Asp Cys Phe Gly Thr Asn Ser Lys Gln 1060 1065 1070		
Ser Val Val Ser Thr Lys Leu Val Asn Glu Ser Leu Ser Gly Ala Thr 1075 1080 1085		
Val Arg Asp Glu Lys Ile Asn Thr Lys Ser Met Arg Asn Ser Ser Glu 1090 1095 1100		
Asp Glu Glu Cys Met Thr Glu Lys Arg Cys Ser His Tyr Ser Thr Ala 105 1110 1115 1120		
Thr Arg Asp Ile Glu Lys Thr Ile Ser Gly Ile Lys Lys Lys Tyr Lys 1125 1130 1135		
Lys Gln Val Gln Lys Leu Val Gln Glu His Glu Glu Lys Lys Met Glu 1140 1145 1150		
Leu Leu Asn Met Tyr Ala Asp Lys Lys Gln Lys Leu Glu Thr Ser Lys 1155 1160 1165		
Ser Val Glu Ala Ala Val Ile Arg Ile Thr Cys Ser Arg Thr Ser Thr 1170 1175 1180		
Gln Val Gly Asp Leu Lys Leu Leu Asp His Asn Tyr Glu Arg Lys Phe 185 1190 1195 1200		
Asp Glu Ile Lys Ser Glu Lys Asn Glu Cys Leu Lys Ser Leu Glu Gln 1205 1210 1215		
Met His Glu Val Ala Lys Lys Lys Leu Ala Glu Asp Glu Ala Cys Trp 1220 1225 1230		
Ile Asn Arg Ile Lys Ser Trp Ala Ala Lys Leu Lys Val Cys Val Pro 1235 1240 1245		
Ile Gln Ser Gly Asn Asn Lys His Phe Ser Gly Ser Ser Asn Ile Ser 1250 1255 1260		
Gln Asn Ala Pro Asp Val Gln Ile Cys Asn Asn Ala Asn Val Glu Ala 265 1270 1275 1280		
Thr Tyr Ala Asp Thr Asn Cys Met Ala Ser Lys Val Asn Gln Val Pro 1285 1290 1295		
Glu Ala Glu Asn Thr Leu Gly Thr Met Ser Gly Gly Ser Thr Gln Gln 1300 1305 1310		

Val	His	Glu	Met	Val	Asp	Val	Arg	Val	Asn	Asp	Glu	Thr	Met	Asp	Val	Ser											
1315												1320				1325											
Ala	Leu	Ser	Arg	Glu	Gln	Leu	Thr	Lys	Ser	Gln	Ser	Asn	Glu	His	Ala												
1330												1335				1340											
Ser	Ile	Thr	Val	Pro	Glu	Ile	Leu	Ile	Pro	Ala	Asp	Cys	Gln	Glu	Glu												
345												1350				1355				1360							
Phe	Ala	Ala	Leu	Asn	Val	His	Leu	Ser	Glu	Asp	Gln	Asn	Cys	Asp	Arg												
				1365												1370				1375							
Ile	Thr	Ser	Ala	Ala	Ser	Asp	Glu	Asp	Val	Ser	Ser	Arg	Val	Pro	Glu												
				1380												1385				1390							
Val	Ser	Gln	Ser	Leu	Glu	Asn	Leu	Ser	Ala	Ser	Pro	Glu	Phe	Ser	Leu												
				1395																1400				1405			
Asn	Arg	Glu	Glu	Ala	Leu	Val	Thr	Thr	Glu	Asn	Arg	Arg	Thr	Ser	His												
1410												1415								1420							
Val	Gly	Phe	Asp	Thr	Asp	Asn	Ile	Leu	Asp	Gln	Gln	Asn	Arg	Glu	Asp												
425												1430								1435				1440			
Cys	Ser	Leu	Asp	Gln	Glu	Ile	Pro	Asp	Glu	Leu	Ala	Met	Pro	Val	Gln												
				1445																1450				1455			
His	Leu	Ala	Ser	Val	Val	Glu	Thr	Arg	Gly	Ala	Ala	Glu	Ser	Asp	Gln												
				1460																1465				1470			
Tyr	Gly	Gln	Asp	Ile	Cys	Pro	Met	Pro	Ser	Ser	Leu	Ala	Gly	Lys	Gln												
				1475																1480				1485			
Pro	Asp	Pro	Ala	Ala	Asn	Thr	Glu	Ser	Glu	Asn	Leu	Glu	Glu	Ala	Ile												
1490												1495								1500							
Glu	Pro	Gln	Ser	Ala	Gly	Ser	Glu	Thr	Val	Glu	Thr	Thr	Asp	Phe	Ala												
505												1510								1515				1520			
Ala	Ser	His	Gln	Gly	Asp	Gln	Val	Thr	Cys	Pro	Leu	Leu	Ser	Ser	Pro												
				1525																1530				1535			
Thr	Gly	Asn	Gln	Pro	Ala	Pro	Glu	Ala	Asn	Ile	Glu	Gly	Gln	Asn	Ile												
				1540																1545				1550			
Asn	Thr	Ser	Ala	Glu	Pro	His	Val	Ala	Gly	Pro	Asp	Ala	Val	Glu	Ser												
				1555																1560				1565			
Gly	Asp	Tyr	Ala	Val	Ile	Asp	Gln	Glu	Thr	Met	Gly	Ala	Gln	Asp	Ala												
1570												1575								1580							
Cys	Ser	Leu	Pro	Ser	Gly	Ser	Val	Gly	Thr	Gln	Ser	Asp	Leu	Gly	Ala												
585												1590								1595				1600			

WO 01/00801

PCT/EP00/05761

- 21 -

Asn Ile Glu Gly Gln Asn Val Thr Thr Val Ala Gln Leu Pro Thr Asp  
1605 1610 1615

Gly Ser Asp Ala Val Val Thr Gly Gly Ser Pro Val Ser Asp Gln Cys  
1620 1625 1630

Ala Gln Asp Ala Ser Pro Met Pro Leu Ser Ser Pro Gly Asn His Pro  
1635 1640 1645

Asp Thr Ala Val Asn Ile Glu Gly Leu Asp Asn Thr Ser Val Ala Glu  
1650 1655 1660

Pro His Ile Ser Gly Ser Asp Ala Cys Glu Met Glu Ile Ser Glu Pro  
665 1670 1675 1680

Gly Pro Gln Val Glu Arg Ser Thr Phe Ala Asn Leu Phe His Glu Gly  
1685 1690 1695

Gly Val Glu His Ser Ala Gly Val Thr Ala Leu Val Pro Ser Leu Leu  
1700 1705 1710

Asn Asn Gly Thr Glu Gln Ile Ala Val Gln Pro Val Pro Gln Ile Pro  
1715 1720 1725

Phe Pro Val Phe Asn Asp Pro Phe Leu His Glu Leu Glu Lys Leu Arg  
1730 1735 1740

Arg Glu Ser Glu Asn Ser Lys Lys Thr Phe Glu Glu Lys Lys Ser Ile  
745 1750 1755 1760

Leu Lys Ala Glu Leu Glu Arg Lys Met Ala Glu Val Gln Ala Glu Phe  
1765 1770 1775

Arg Arg Lys Phe His Glu Val Glu Ala Glu His Asn Thr Arg Thr Thr  
1780 1785 1790

Lys Ile Glu Lys Asp Lys Asn Leu Val Ile Met Asn Lys Leu Leu Ala  
1795 1800 1805

Asn Ala Phe Leu Ser Lys Cys Thr Asp Lys Lys Val Ser Pro Ser Gly  
1810 1815 1820

Ala Pro Arg Gly Lys Ile Gln Gln Leu Ala Gln Arg Ala Ala Gln Val  
825 1830 1835 1840

Ser Ala Leu Arg Asn Tyr Ile Ala Pro Gln Gln Leu Gln Ala Ser Ser  
1845 1850 1855

Phe Pro Ala Pro Ala Leu Val Ser Ala Pro Leu Gln Leu Gln Gln Ser  
1860 1865 1870

Ser Phe Pro Ala Pro Gly Pro Ala Pro Leu Gln Pro Gln Ala Ser Ser  
1875 1880 1885

Phe Pro Ser Ser Val Ser Arg Pro Ser Ala Leu Leu Leu Asn Phe Ala



<223> Description of Artificial Sequence:Synthetic

WO 01/00801

PCT/EP00/05761

- 24 -

Oligonucleotide

<400> 10  
wggwancwga wangca 16

<210> 11  
<211> 16  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence:Synthetic  
Oligonucleotide

<400> 11  
wcgwwgawca ngncga 16

<210> 12  
<211> 16  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence:Synthetic  
Oligonucleotide

<400> 12  
wgcnagtnag wanaag 16

<210> 13  
<211> 16  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence:Synthetic  
Oligonucleotide

<400> 13  
awgcangncw ganata 16

<210> 14  
<211> 24  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence:Synthetic  
Oligonucleotide

<400> 14

25



WO 01/00801

PCT/EP00/05761

- 26 -

<210> 19  
<211> 25  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence:Synthetic  
Oligonucleotide

<400> 19  
gctcttttgta agctgttcac gagac

25

<210> 20  
<211> 24  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence:Synthetic  
Oligonucleotide

<400> 20  
tcgcatgatg ttaagcacgt agag

24

<210> 21  
<211> 25  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence:Synthetic  
Oligonucleotide

<400> 21  
gagtactggt ccgtgaacag gtaat

25

<210> 22  
<211> 25  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence:Synthetic  
Oligonucleotide

<400> 22  
atgcttgac aagcatggtc ggaaa

25

<210> 23  
<211> 25  
<212> DNA

gaattcctgn	nttacggcat	cttaataaga	ctgttcaaat	ggaactcctg	aacctggggt	60
tccactccca	tggaagtgtt	ccagcttatc	aaataaatat	gatgcccccc	acatgagcaa	120
tgcattgtgtg	agaggacggt	ttaggttctc	tagaggctta	ttttgcctag	caagaatcag	180
ggttttttct	tcaactgtaa	acactgagta	caaccggaaa	atcttagtct	tttcagaaca	240
cgactcaacc	tttatcttct	ctaagagctt	aacgtcatgc	gatggattca	ggctgcttcc	300
aaaaagtata	aaagactcag	cgcgtaagag	tttaattgctt	tgactacagg	cacgtatttc	360
cagcagcaga	ataaaaacat	cactctcctt	gttgaaattg	tttatagcgt	tcttcttcga	420
gaggcagacc	ccatgctcat	aggaattttg	accaaactctt	tgcatcagaa	aatcttcgag	480
aatattacca	agcagaagcc	cttcagggct	atgtatttgc			519

WO 01/00801

PCT/EP00/05761

- 28 -

<210> 27  
<211> 419  
<212> DNA  
<213> Brassica oleracea

<220>  
<223> seq1-27

<400> 27  
gaattcagga tcaaaagggt tgccgggttg agaaactggt ttagagaaag gctctgattt 60  
tcctgtggaa gtaactaagg atatagagaa gacagtgggt gattcatccc ccatgggtga 120  
aactgaggat ggcagtgtta taggttcacc atccgagaat ccagaaccac aaaagcttcg 180  
tgacagtga actagcttgg aaaccgatat agacttggct ctgaaaagaa aaagagacac 240  
tgcagaaatt gtgatggatg catgtacaaa tgcagatgac cgcattatga gtactgatgg 300  
ggttattcct ttccaccgg tgtgcacaaa tattaatcaa cccgaaagggt gtggcacatg 360  
tcaaaaacgg caaaagtaag aatttccgac tgttgtctgt cgttttgaaa ccatttgcc 419

<210> 28  
<211> 467  
<212> DNA  
<213> Brassica oleracea

<220>  
<223> seq1-43

<400> 28  
gaattctcgt ccatactttc ttccgatgtt ggagaagaaa atgaaggcaa gctgtgtcta 60  
cttttggaag ccaagcatgc tcagggaaagt tacagcactg atgctactct atttggtgaa 120  
gaacatgtca agttatcaga tgaaagtcca aatatgtttt ggtcaaagct gttgagtggg 180  
aagaacccta tgtggaaata ctgttcggat actcctcaaa ggagtcgaaa aagagtacgg 240  
catcttcagg gctatgagga gactacaaa gttggcaatg gcggaaactt aaagaagaaa 300  
aagaaggctt cagatgatgt cacagtagat aacgctgaga gaaaagcctc tggaaaggat 360  
cacatgggta aaacagttca cttcctgctc ctttacctct agtgttcatt gaatgttcca 420  
tttactttgc ttactatctt tccttcaggg catttgaggt caccaaa 467

<210> 29  
<211> 490  
<212> DNA  
<213> Brassica oleracea

<220>  
<223> seq1-47

<400> 29  
gaattcagct tttaaaactg atctctgctc acagataatt taagagtcag tgaaaattga 60  
gataaaacga accaaaactg gaggtaacag atactctgag aacaactaac cttttcttca 120  
taagtcttct ttgtgttctc tgattctctc cgcagcttct ccagttcatg ctgaaatggg 180  
tcaactgaaca cagggaagg tacttgagga acaggtggag tggcattctg tcccgtagca 240  
ttgttaagct gtgaagaaac aggagctgtt acacctgctg gaggtccac aacaccttca 300  
tcgacaacgt ctgcgtaaaa ggtattacca gattgtcagt ttctctggca aacacatacg 360  
ttatacttaa atgcaaaaga gcagttactg acttgcaaag gttggttgtt ctacttgagc 420  
atcaggttct gctacttcca ttccacatgc ttctgatcca gttgtgcgag gcgcagccat 480

WO 01/00801

PCT/EP00/05761

- 29 -

tggttggttg

490

<210> 30  
<211> 515  
<212> DNA  
<213> Brassica oleracea

<220>  
<223> 2-33

<400> 30  
tctagagaag aggtggatta tgtatattct tttctgtact gcatgaagag tctattcgtg 60  
ggcgccacac aagggtttcca agaaaagggt gaagaatgca tggctgagaa aagaggtagc 120  
cattatagct cagtaaccaa ggatgttgaa aagactatta gcgacatcaa aaagaaatgc 180  
agtaagagcc tgcataagct tgtacaaaacc ctcgaggaag aaaagatgga cctgatgaat 240  
aggaatgctg tcaagaagca ggaacttcag aattgtaaaa aggtggaagc atcattttatt 300  
cgtgtcacct attcaggtat aaatactcag agcttacatg atgctctcca acggctggaa 360  
tgtacttttg aaagaaagtt tgatgatctc aaaggagagt tggatgaatg ccttgaaagt 420  
ttagagcaaa taaacgagggc tggaaagaag aagttggctg aagatgaagc ctgttggatt 480  
agtcggatag agaaatgggc acgagctgaa ttaag 515

<210> 31  
<211> 574  
<212> DNA  
<213> Brassica oleracea

<220>  
<223> seq2-37

<400> 31  
tctagaccac actattaaac gctaaacata agaagattag atcactcgtc atcagagaga 60  
cagaccacat cattgtctct ctgcaatcca ctccccaagt tctgtggttg ttcttgctgc 120  
tgaataaacg catttgaata tggtaaaggg ttggagatga gaggttgtct tggttgaggc 180  
attgtgcagt acggagccga agcagtatga ttcttcagtg cgcttacttg tgttgctctc 240  
tgtgctagct gctggattct aactggagaa agaaaaaaag aaaaaaaagg tgttattatg 300  
acttcataac cttatatctt taaaaaacia ttatgcttct attattcgaa cacttgccca 360  
ttggagttgc tgctgaggaa tgagaggaga ttctgctcgt acatttagac aagaacgcac 420  
tcgacaacag cttgttcttt ataacaagat tcttcctcgt ctgtaacttc gtctttctgg 480  
ctgcatgtac agcttgatcc tcatgaaact ttctctgata ctcttcttgt aattcagcta 540  
tcttcttctc gaatttagct ttcaagactg cttt 574

<210> 32  
<211> 466  
<212> DNA  
<213> Brassica oleracea

<220>  
<223> seq2-53

<400> 32  
tctagattgt aattttaaat ttacaacaaa ttttgaaagg gtcagcgatg agtttgcaaa 60  
tctccgtgtt tctccagca ttgctcagcc agttcaagaa cctgatcact tggcacaggt 120

<400> 33						
tctagagcaa	ttgaaaccta	attccgattt	tgcgcgggcc	agagattctt	cacggttgaa	60
cttttgctta	acgaaagaga	ctgcaatcca	aatctggaag	tgcattatta	agaacgtatt	120
cagcaatatt	cataaattat	gcaacaatca	aaggccttac	gttgtggcct	acaaagcatg	180
gattttgtta	gatattagta	gctagtctaa	ttcaagcaat	taatggaagt	ttctatccta	240
tgactggaaa	gttaaacatt	cccacaaaag	cagtgtatgc	acagatgatg	aagaagaaaa	300
atgcataac	tatggaagtg	aatgctatca	tccacacagct	atctggaagg	cctgcaatgt	360
tgtagctggc	tctttgcaga	cacggtgggt	gtcaataata	tattcaagaa	ctttttc	417